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1. INTRODUCTION
MuchhasbeenmadeaboutJ.L.W.Thudichum’scolorful,and
one could say clairvoyant, naming of sphingosine “in commem-
oration of the many enigmas which it presented to the inquirer”
in his 1884 treatise The Chemistry of the Brain
1 because many of
the riddles of sphingolipids (as the broader ﬁeld was later
named)
2 remained unanswered for the following century. This
changed radically over the past several decades as researchers
explored, and ultimately established, what seemed at the time to
be radical concepts: that sphingolipids are not just structural
elements of cells but also participate in intra- and extracellular
signaling; that not only the complex glycan headgroups, but also
the lipid backbones, are highly speciﬁed metabolically and have
selectivebiochemicalfunctions;andthateventhelongestknown
function of these lipids, as structural components of the “ﬂuid
mosaic” of cell membrane lipids, is not so simple, and often
involves the dynamic clustering of sphingolipids in nontradi-
tional microdomains referred to as rafts. We still know only a
fraction of their secrets, but this enlightenment has deﬁned
models for thinking about these compounds that remove them
from their enigmatic “black box.”
Now, a major challenge is to keep up with the rapid growth in
knowledgeaboutthesphingolipidome,thatis,theensembleofall
sphingolipids.
3 A major goal of the review is to help the reader
more easily grasp the metabolic interrelationships that account for
the tens of thousands of molecular subspecies (and perhaps more)
that appear in nature, with a focus on mammals. The magnitude
of this subject precludes the inclusion of all of the enzymes and
metabolites, and the author apologizes for the omission of many
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interesting topics. To put this information in context, there is a
brief background discussion of their structures and functions,
which have been dealt with also in a recent Chemical Reviews
article
4 on the chemicophysical features of sphingolipids and raft
formation, and by excellent reviews on sphingolipid signaling
5,6
and the biological functions of complex glycosphingolipids.
7 10
2. AN OVERVIEW OF SPHINGOLIPID STRUCTURE AND
FUNCTION
Sphingolipids share the common structural feature that all are
comprised of backbones called “long-chain-” or “sphingoid”
bases, which are represented by sphingosine, (2S,3R,4E)-2-
aminooctadec-4-ene-1,3-diol (also referred to as (E)-sphing-4-
enine) 1, the major sphingoid base found in mammals. Free
sphingoid bases (i.e., underivatized) are typically present in very
small amounts because most are amide-linked with a long- or
very-long-chainfattyacidtoformceramides2thatcanbefurther
derivatizedbyadditionofaheadgroup(atC1in2)toformmore
complex sphingolipids such as sphingomyelin (SM), glucosyl-
ceramide (GlcCer), galactosylceramides (GalCer) and more
complex glycosphingolipids with a few to dozens of sugar
residues.
3 There are also small amounts of “lyso-”sphingolipids
(i.e., sphingoid bases plus a headgroup but lacking the N-acyl-
substituent, such as sphingosine 1-phosphate, sphingosine
1-phosphocholine, and lyso-glycosphingolipids), N-methyl-deri-
vatives, and covalent adducts with proteins.
2.1. Backbone and Headgroup Nomenclature
Because organisms usually have more than one type of
sphingoid base (e.g., not just sphingosine 1, but also sphingoid
bases with more or fewer hydroxyls, somewhat shorter or longer
alkyl chains, and other structural variations),
11 a convenient
short-hand nomenclature to distinguish them by these features
istogivethenumberofhydroxylgroups(mforone,mono-,dfor
thetwo,di-,andtforthree,tri-)followedbythechainlengthand
number of double bonds (with their position, if necessary).
Therefore, sphingosine 1 is usually abbreviated d18:1, with the
double bond assumed to be at position 4, or speciﬁed by a preﬁx
(4E-d18:1)orsuperscriptedsuﬃx(d18:1
Δ4t).Theadditionofan
amide-linkedfattyacidtoformaceramidecanbedesignatedbya
semicolon or slash followed by the carbon chain length and
number of double bonds for the fatty acid. Using this nomen-
clature, the Cer 2 (N-palmitoylsphingosine) would be abbre-
viated d18:1;C16:0 (or d18:1/C16:0, or 4E-d18:1;C16:0,
etc.). This can be added to the name of the sphingolipid
headgroup subcategory (as shown in Figure 1 for ganglioside
GM1a)toprovideexplicitinformationaboutthemoleculethat
is being described.
Themajorheadgroup typesand someaspects of theirnomen-
clature are shown in Figure 1. They can be categorized as having
substituents that are nonpolar (H- and O-acyl) versus polar
(phospho- and glyco-) or polar with an ionic group (phosphate,
carboxyl for N-acetylneuraminic acid and glucuronic acid, or
sulfate). The phosphosphingolipids of mammals are ceramide
1-phosphate (Cer1P), sphingomyelins (SM) and ceramide
phosphoethanolamines (CerPE) (plus the “lyso” forms of these,
that is, with the sphingoid base but not amide linked fatty acid).
The glycosphingolipids are divided into multiple subcategories:
ﬁrst by whether they have glucose (GlcCer) or galactose
(GalCer) as the carbohydrate attached in β-linkage to Cer, then
bythenatureoftheadditionalsubstituents(forexample,sulfated
glycosphingolipids are referred to as sulfatides). GlcCer is followed
by addition of Gal to form Galβ1 4Glcβ1Cer (lactosylceramide,
LacCer), which is at a branchpoint for formation of the so-called
root structure families (globo-, isoglobo-, lacto-, neolacto-, and
ganglio-) shown in Figure 1. Likewise, the order and position
of addition of other substituents, in particular the addition of
N-acetylneuraminicacid(Neu5Ac,whichisalsocalledsialicacid)
deﬁnes branching families of glycosphingolipids (in this case,
gangliosides), with ganglioside GM1a shown as an example in
Figure 1 as both a chemdraw structural diagram and commonly
usedsymbols (seekey inFigure 1).
12Itis worth mentioningthat
there are structural diﬀerences in the repertoire of carbohydrates
that are used among even fairly closely related mammals, for
example, the sialic acid of human gangliosides is primarily
comprised of N-acetylneuraminic acid (Neu5Ac) as shown for
GM1a in Figure 1 whereas other mammals have both Neu5Ac
and N-glycolylneuraminic acid (abbreviated Neu5Gc), which
cannot be made by humans.
13
Many of the glycosphingolipids are comprised of the same
units attached in diﬀerent combinations and arrangements, as
exempliﬁed in Figure 1 by the root structure families globo-
versusisoglobo-andlacto-versusneolacto-(aswellasbythetwo
gangliosides GM1a and GM1b) and, thus, glycosphingolipid
biosynthesis has been described as nature’s version of combina-
torial chemistry.
14
There are several nomenclature systems for glycosphingoli-
pids, and many compounds are still referred to by their histori-
cally assigned names (such as gangliosides GM1a and GM1b
shown in Figure 1). Using IUPAC-IUB guidelines for systematic
naming of glycosphingolipids,
15,16 these gangliosides would
bedescribedasNeu5Acα2 3(Galβ1 3GalNAcβ1 4)Galβ1 
4Glcβ1Cer (d18:1/C18:0) for GM1a, and Neu5Acα2 3Galβ1 
3GalNacβ1 4Galβ1 4Glcβ1Cer(withthesameCerbackbone
speciﬁcation, if it applied) for GM1b. These compounds could
also be named starting with the Ganglio (Gg) root structure that
they both share (see insert in the upper right of Figure 1) with
designationofthelocationoftheNeu5NAcalongthechainusing
Roman numerals (this numbering system is shown for GM1a)
and Arabic superscripts to designate the hydroxyl- to which the
Neu5NAc is linked. By this system, GM1a is described as II
3-α-
Neu5NAc-Gg4Cer (which would be read “II
3-α-N-acetylneur-
aminosyl-gangliotetraosylCer”) and GM1b is IV
3-α-Neu5NAc-
Gg4Cer (IV
3-α-N-acetylneuraminosyl-gangliotetraosylCer). When
there are additional modiﬁcations, such as 9-O-acetylation of sialic
acid
13,17 or formation of an intramolecular lactone,
18 these are
added to the name. Some other glycans that are still referred to
by historicnamesaretheLewisbloodgroupantigens(Figure2).
19,20
Thebiologicalrationalebehindthisstructuralcomplexityisno
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of sphingolipids, as represented schematically in Figure 3. Com-
plex sphingolipids (shown here as SM, in black, and gangliosides
GM3 and GM1a, using the headgroup key from Figure 1) help
form lipid bilayers with unique surface characteristics (charge,
polarity and morphology) and ﬂuidity, which contribute to the
clustering of sphingolipids and cholesterol (and some proteins)
in rafts.
4,21 Also depicted are interactions between surface glyco-
sphingolipids and proteins on the same cell, the extracellular
matrix, neighboring cells, and otherentities (such as bacterial toxins
andviruses),whichhavebeenreferredtoasthe“glycosynapse.”
22
Sphingolipids additionally contribute to membrane dynamics
23 and
cell regulation through metabolic interconversions (shown for
SM and Cer, which can occur via sphingomyelinases and SM
synthase)
24 and membrane traﬃcking,
21,25 and this can lead to
production of additional bioactive metabolites (Cer1P, sphingo-
sine and S1P)
26 that act in situ, inside, or outside of the cell
(as shown for S1P and an S1P receptor).
6 Although these
functions (both of the complex sphingolipids and the “signaling”
lipid moieties) are shown at the plasma membrane, where they
certainly can occur,
27 the lipid backbones from de novo sphin-
golipid biosynthesis also contribute to signaling
28 (sometimes
with deleterious consequences),
29 and sphingolipids have func-
tions in previously unexpected organelles such as the nucleus,
30
and in some cases using enzymes classically thought to be active
only for “housekeeping” turnover of sphingolipids, such as acid
sphingomyelinase.
31 It will be a challenge to ﬁgure out which
speciﬁcsphingolipidmolecules(andcombinationsofmolecules)
are present and interacting with which speciﬁc targets to achieve
the sphingolipid-regulated steps in a biological process.
2.2. Variation in the Lipid Moieties
Some of the breakthroughs in understanding the functions of
sphingolipids, especiallywithrespect tocellsignaling, have come
from having the capacity to measure more than one bioactive
subspecies so the correct signaling pathways can be sorted out,
32
especially when the metabolites have opposite eﬀects, such as
ceramide versus S1P.
33 In recent years, the analytical technology
of choice has been mass spectrometry;
34,35 however, even when
the analysis of the lipid moieties of sphingolipids was quite
Figure 1. Basic structures of mammalian sphingolipids. The upper left panel summarizes the categories of complex sphingolipids, and the upper right
paneldisplaystherootstructuresoftheglycosphingolipidfamiliesusingtheglycansymbolsdeﬁnedbythekeyinthelowerpanel(theletterandnumber
within the symbols convey the nature of the glycosidic linkage between that carbohydrate and the species to its right, for example: “β4” represents
a β1 4 linkage). The abbreviations are: Glc, glucose; GlcNAc, N-acetylglucosamine; Gal, galactose; GalNAc, N-acetylgalactosamine; Neu5Ac,
N-acetylneuraminic acid; Fuc, fucose. The lower panel displays the structure of ganglioside GM1a using both ChemDraw and glycan symbols, the
Roman numbering system for the positions of the glucans (i.e., beginning with the ﬁrst carbohydrate attached to ceramide), and a comparison with
two other gangliosides (GM1b and fucosyl-GM1a) using the glycan symbol system.
Figure 2. Representative structures of Lewis epitopes. The key for the
glycan symbols is the same as for Figure 1.6390 dx.doi.org/10.1021/cr2002917 |Chem. Rev. 2011, 111, 6387–6422
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laborious (for example, usingchemicaldegradation todetermine
sphingoidbasecomposition),
36,37thefewbiologicalsamplesthat
were examined in depth gave an astonishing result, that is, that a
given class of sphingolipid is comprised of dozens of diﬀerent
backbones, not just the handful that are usually discussed.
38
Indeed, a recent analysis of human plasma SM using a mass
spectrometry protocol that is able to distinguish the isobaric and
isomeric subspecies (using a technique we refer to as “ion trap
facilitated fragmentation”)
39 identiﬁed ∼100 diﬀerent lipid
subspecies,
40 and other types of mass spectrometry have un-
covered an equivalent level of structural diversity with mamma-
lian samples.
41
2.2.1. Sphingoid Base Diversity. Sphingoid bases vary in
type (such as sphingosines versus sphinganines) (Figure 1) and
chain length. Two of the most common chain length variants of
sphingosine (d18:1) 1 are d16:1, which has been found, for
examples, in plasma sphingolipids
40,42 and bovine milk,
43,44 and
d20:1 (eicosasphingosine), which is present in substantial
amounts in brain gangliosides, especially with advanced age.
45
Otherlocationsincludehumanstomachandintestinalmucosa,
46
skin ceramides,
47 sulfatides,
48 and perhaps most puzzlingly, in
host liver SM from rats bearing Morris hepatoma 7777.
49
Mammalian sphingoid bases also include odd chain length
variants (e.g., linear d17- and d19-, but odd carbon numbers
are sometimes due to branched alkyl chains) and shorter chain-
length subspecies(which arein traceamountsin mammals,but
more common in other organisms, such as Drosophila
50).
11
This variation has important implications for analysis of sphin-
golipidsbymassspectrometry,whichfollowsspecificmolecular
ions and fragmentation products (often as precursor-product
pairs)
40 so the bookkeeping of how much of a particular category
of sphingolipid is present (for example, all the SM’s) will depend
on successful inclusion of all of the subspecies in the analysis
protocol (within the detection limits selected by the investi-
gator).
Little is known about the biological signiﬁcance of this
seemingly subtle backbone chain-length variation, however,
the alkyl-chain length mismatch has substantial biophysical
consequences.
51 And if selective anatomical localization of
d20:1 sphingosine is an expression of the adage that “form
follows function,” it is noteworthy that gangliosides from
sensory nerve contain larger proportions of d18:1 than motor
nerve gangliosides (which have higher d20:1).
52 The very
powerful technique of tissue-imaging mass spectrometry has
established that d20:1 gangliosides are selectively localized
along the entorhinal-hippocampus projections, especially in
the molecular layer of the dentate gyrus, whereas those with
the18-carbonsphingoidbasebackbonearewidelydistributed
throughout the frontal brain.
53
Other types of structural variations that have been found in
humansareshownin3to7(thesealsoappearinotheralkylchain
lengths).
11
Sphinganine (also referred to as dihydrosphingosine) 3 is an
intermediate of sphingoid basebiosynthesis andisfoundinmost
complex sphingolipids in at least small amounts; 4-hydroxy-
sphinganine 4, which is often referred to as phytosphingosine, is
commonly found in sphingolipids from epithelial tissues
54 and
skin (which also has another trihydroxy-sphingoid base with the
extra hydroxylation at postion 6 rather than 4, 5).
47,55 58 In
addition to these, the diene 6 has been noted in plasma
40
and brain,
59,60 and other mammalian sources.
61 Sphingadienes
Figure 3. Schematic representation of sphingolipid functions. This
diagram depicts a hypothetical plasma membrane with representative
categories of sphingolipids with the black headgroup representing
sphingomyelin, the colored headgroups the glycosphingolipids as in
Figure1,andthelipidbackboneswiththesphingoidbaseinblueandthe
amide-linkedfattyacidingray;phosphoglycerolipidsandcholesterolare
depictedingray.Thediagramillustratestheclusteringofaportionofthe
sphingolipids (and cholesterol) in membrane “rafts,” the binding of
ganglioside GM3 (left) and GM1 (right) to proteins, and the metabolic
interconversions of some of the sphingolipids (shown in the box, in the
order ceramide 1-phosphate, ceramide, sphingosine, and sphingosine
1-phosphate, S1P), which alters both the biophysical properties of the
membrane and generates signaling molecules, such as S1P, which is
involved in both intracellular signaling and extracellular signaling
(represented by the green arrow).6391 dx.doi.org/10.1021/cr2002917 |Chem. Rev. 2011, 111, 6387–6422
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withdoublebondsatotherpositions
62 64(andtrienes)
65arefound
in plants, and have been reported in SM from human breast milk.
66
Sphingoid bases 7 and 8 have been found in mammals only
recently,
67,68 and are very intriguing because they lack the 1-hydro-
xyl-group that is found on all of the other sphingoid bases, which
means they (or the N-acyl-“1-deoxydihydroceramide” deriva-
tives) can not be metabolized to more complex sphingolipids by
headgroup addition. They are mainly present as the N-acylated
(1-deoxydihydroceramide) metabolites,
67 which will be extremely
hydrophobic. It is not clear how they are catabolized since degrada-
tion of the typical sphingoid bases proceeds via the 1-phosphates.
69
Some of the structural variety found with other organisms
11,36,37
is illustrated by examples 9 12. The branched triene 9 has been
identiﬁed in squid nerve sphingomyelin,
70 aplidiasphingosine 10
hasbeenisolatedfromthemarinetunicateAplidiumsp.
71,72andnoted
tohaveantimicrobialandantitumorialactivity,
71,73andobscuraminol
11 was isolated from a chloroform extract of Pseudodistoma
obscurum
74 that was cytotoxic for various tumor cell lines (but
the isolated compound was only mildly cytotoxic). Calyxinin 12
is a member of a fascinating series of compounds that resemble
“two-headed” sphingoid bases, that is, two sphingoid bases
connected tail-to-tail (note that the lower portion of calyxinin
resemblessphinganinetheupperportiona1-deoxysphinganineat
the other end with threo- stereochemistry).
75 These and other extra-
ordinary sphingoid bases
11 warrant attention because they
might be useful tools for studies of sphingolipid metabolism or
functions (as will be discussed below for two stellar examples,
fumonisin B1 13 and myriocin 14). Furthermore, some might
appearinhumansifconsumedinthediet(or, perhaps, produced
de novo but previously overlooked). Indeed, both apply to
1-deoxysphinganine 7, which was ﬁrst named spisulosine upon
its isolation from Spisula polynyma,
76 a clam that is consumed by
humansassushi,chowderand“clamstrips”(appearinginrecipes
astheArcticsurfclamorStimpson’ssurfclam).Itwaslaterfound
to be made by mammals.
67,68
The fungal secondary metabolites fumonisin B1 13 and
myriocin 14 are the two most widely studied extraordinary
sphingoid bases. Soon after the structure of fumonisin B1 was
elucidated,
77itssimilaritytosphinganineledtoRonRileyandmy
laboratories to explore if it might aﬀect sphingolipid metabolism
and the discovery that fumonisins are potent inhibitors of
ceramide synthase.
78 Furthermore, this inhibition is thought to
be a major contributor to the diseases caused by this family of
mycotoxins, including a recent association with birth defects.
79
Fumonisin B1 has been employed in hundreds of studies of
sphingolipidmetabolism,andisausefultooliftheinvestigatorbears
inmindthatitalsocausesaccumulationofsphingoidbasesandoften
their 1-phosphates.
80 Likewise, myriocin (also called ISP-1) has
been of tremendous value in sphingolipid research as a potent
inhibitor of serine palmitoyltransferase,
81 83 and studies of immu-
nosuppression by myriocin
81,83,84 led to the development of
FTY720 (Fingolimod) 15, a compound that undergoes phosphor-
ylation and disrupts lymphocyte traﬃcking by binding to S1P
receptor(s).
85FTY720hasshownpromiseintreatmentofanumber
of diseases, including multiple sclerosis.
85,86 Interestingly, cis-4-
methylsphingosine 16 is another sphingoid base analog that is
readily taken up by cells, undergoes phosphorylation, and aﬀects
S1Preceptors;
87italsoinhibitsdenovosphingolipidbiosynthesis.
88
Thus, many of these compounds might serve as pharmaco-
phors for development of novel therapeutic agents. The sphin-
goid base saﬁngol (L-threo-sphinganine) 17 was one of the ﬁrst
sphingoid base analogs to be tested as a potential anticancer
agent because it inhibits protein kinase C and has a longer half-
life than naturally occurring sphingoid bases (and is now of6392 dx.doi.org/10.1021/cr2002917 |Chem. Rev. 2011, 111, 6387–6422
Chemical Reviews REVIEW
interest also because it inhibits sphingosine kinase and induces
autophagy).
89,90 Saﬁngol has been evaluated in a phase I clinical
trial alone and in combination with cisplatin and, in addition to
deﬁning the dosages that can be administered safely, the studies
found that Saﬁngol caused a dose-dependent reduction in S1P,
as predicted.
91 A synthetic 1-deoxy-sphingoid base analog,
Enigmol
92 18, has shown eﬃcacy against using colon and pro-
statecancerinmousemodels.And,phaseIclinicaltrialshavealso
beenconductedwith1-deoxysphinganine7(underthenameES-
285),
93,94whichsurfacedinascreenoflipidextractsfromaquatic
organisms for potential anticancer compounds.
95
The mechanisms of action of sphingoid bases have been
diﬃcult to pin down because they aﬀect many targets, which
include receptors, protein kinases and ion transporters,
96 98 and
because they are metabolized to and from other highly bioactive
compounds (Cer, S1P, and others) (as depicted in Figure 3).
Sphingolipids are also produced by yeast, and an understanding
of signaling by free sphingoid bases is becoming clearer for that
organism.
99
2.2.2. N-Acyl-sphingoid Bases (Ceramides). Acylation of
the amino group of sphingoid bases with a fatty acid produces
compounds broadly referred to as “ceramides” 2, although
another current convention is to use this term specifically for
N-acylsphingosines, and to apply other descriptors when a
different sphingoid base is present, such as dihydroceramides
for N-acylsphinganines and 4-hydroxyceramides or phytocera-
mides for N-acyl-4-hydroxysphinganines. The fatty acid chains
are predominately 14 to 36 carbon atoms in length, and usually
saturated, or with a single double bond or an α-hydroxyl group.
Some of the most structurally complex ceramides are found in
skin,whichincludesthepresenceofavery-long-chainfattyacid
(C30 to 32) with an ω-hydroxyl group that is esterified to
another fatty acid,
100 102 and in testis, which contains neutral
glycosphingolipids with very-long-chain (C26 to C32) poly-
unsaturated(4to6doublebonds)fattyacids.
103,104Ceramides
withveryshortfattyacids,asshortastwocarbons(acetyl-,C2-
C e r ) ,h a v ea l s ob e e nf o u n di nm a m m a l s
105 and suggested to
arise from transfer of the acetyl group from platelet-activating
factor.
106
Ceramide nomenclature follows the conventions already dis-
cussed. If the fatty acid is not stated explicitly (e.g., N-palmitoyl-
sphingosine), the fatty acyl-chain length is usually presented as a
preﬁx, such as C16-Cer for N-palmitoylsphingosine, or by the
abbreviated nomenclature described in section 2.1.1. (d18:1/
C16:0, 2).
Synthetic ceramide analogs have been prepared for a wide
range of purposes, including the production of species that are
more readily taken up by cells (e.g., C2-ceramides),
107 for
exploration of structure function relationships in cell signal-
ing,
108 as inhibitors of enzymes of ceramide metabolism
109
(including an interesting case where 1-methylthiodihydrocera-
mide 19 inhibits Cer biosynthesis by inducing sphingosine
kinase),
110 and development of novel compounds that have
shown activity as potential anticancer agents, such as L-threo-
C6-pyridinium-ceramide-bromide 20 (which targets the nu-
cleusandmitochondria),
111the4,6-diene-Cer21
112(i.e.,which
contains an additional trans-double bond between carbons 6
and 7, like the 14-carbon sphingoid base from Drosophila
that has been reported to prevent intestinal tumorigenesis
98)
and N-(40,50-dithiaheptanoyl)-D-erythro-Cer
113 22. Novel
methods of delivery of ceramides (namely, C6-ceramide) have
been developed by preparation of nanoliposomal particles to
facilitatesolubility
114andareshowingeﬃcacyincancerchemo-
therapy.
115,116
The biophysical properties of ceramides include many inter-
esting features,
51 most notably that the alkyl chains are largely
saturated and thus have high phase transition temperatures and
give rise to rigid ceramide-enriched domains in membranes of
otherwise more “ﬂuid” components.
23 These properties are not
generalizable to all “ceramides,” however, and raft stability is
aﬀected by the ceramide N-acyl chain,
117 among other factors.
Ceramides also change membrane curvature,
118 transbilayer
(ﬂip-ﬂop)movementoflipids
119andothermolecules,
120appear-
ing to form channels in mitochondrial outer membranes when
present in suﬃcient concentrations.
120
Cell signaling by ceramides has been elegantly reviewed many
times
5,31,121 125 (just to list a few) and its roles in regulation of
cell growth, senescence and death account for the aforemen-
tioned interest in ceramide analogs and modulators of ceramide
metabolism as potential anticancer agents.
124,126,127 The regula-
tion of autophagy by both ceramide
128,129 and de novo synthe-
sized dihydroceramide
97 is intriguing because this is diﬀerent
than for most of the other cellular processes regulated by ceramide
(e.g., apoptosis), which require the 4,5-trans double bond. This
raises the possibility that cells might use these relatively safe
molecular subspecies for autophagy under conditions where
comparable elevation of ceramides might be dangerous. This
underscores how speciﬁc molecular subspecies are likely to be
important for normal cell function, and the corollary that cells
will have mechanisms to produce and localize the appropriate
subspecies for the necessary structural and regulatory functions.
In the words of Hannun and Obeid in a recent review: “First and
foremost, the ‘Many Ceramides’ approach negates the current
prevailing paradigm that ceramide can beunderstood interms of
regulation and function as a single entity... at the very least
mechanistic studies on ceramide function and regulation should
focusonspeciﬁcpathwaysofformation.”
125Themechanismsfor6393 dx.doi.org/10.1021/cr2002917 |Chem. Rev. 2011, 111, 6387–6422
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formation of speciﬁc ceramide subspecies will be discussed in
section 3.1.
2.3. Variation of the Complex Sphingolipid Headgroups
For the purpose of this review, complex sphingolipids will be
deﬁnedashavingbothofthealkylchains ofthelipidmoiety(i.e.,
“ceramide”) and a substituent at the hydroxyl at position 1. The
major headgroup categories for mammalian sphingolipids
(ceramides, sphingomyelins, glucosylceramides, galactosylcera-
mides, etc.) are summarized in Figure 1, and this shows only a
fraction of the glycan headgroups (Robert Yu has recently com-
piled structures for 174 neutral glycosphingolipids, 190 ganglio-
sides and 24 sulfated glycosphingolipids);
19 the total estimate is
closer to 600 if one adds likely biosynthetic intermediates that
have not yet been characterized (for a depiction of these, see
www.sphingomap.org).
3 The number expands considerably if
one adds headgroups (and backbones) that are found in other
organisms, such as plants,
130 fungi
131 133 and other organisms.
134
Even this summation is likely to underestimate the total as more
sensitive analytical methods allow us to see minor subspecies.
Fortunately(fortheanalyticalchemist),thenumberofspecies
that are produced biologically will be much lower than the
number that could be theoretically made from these glycans (if
all combinations and positional isomers are considered) due to the
relatively limited number of synthases for the complex sphingo-
lipids and their substrate speciﬁcities. For an idea of how many
species might theoretically exist, Roger Laine estimated that six
diﬀerent hexoses could be combined to form >10
12 diﬀerent
hexasaccharides,∼10
15heptasaccharides,>10
18octasaccharides,
and nearly Avogadro’s number for nonasaccharides.
135 Mind-
boggling numbers, indeed! But, as one examines some of the
largest mammalian glycosphingolipids, such as the placental
tetrasialosylpoly-N-acetyllactosaminyl ganglioside 23 shown
here,
136 it is striking that it is comprised of a few repeating units
(for which these types of compounds have been named
“polylactosaminoglycans”).
137
Therefore, one can imagine that there might be a relatively
simple biosynthetic pathway for such compounds with a few
enzymes that act repetitively on the growing chains. This
illustrates how cells might make many complex glycosphingoli-
pids using a relatively small number of glycosyltransferases, and
conversely, how the existence of a ﬁnite number of glycosyl-
transferases determines that cells will produce only a fraction of
the theoretical number of combinations and permutations of the
glycans.
2.3.1.Phosphosphingolipids.Thesimplestcomplexphos-
phosphingolipidisceramide1-phosphate,whichhasnotyetbeen
studied much for molecular subspecies but methods for its
analysis have been developed.
39,138 The N-acyl-chain length of
Cer1P is influenced byits site of synthesis, withthe Cer1P that is
made de novo being enriched in C16-subspecies because it acts
on Cer that have been delivered by the ceramide transport protein
(CERT),
139 which is selective for long-chain versus very-long-
chain Cer. The biological functions of Cer1P are still being
discovered, but include phagocytosis,
140 stimulation of DNA
synthesis,
141 inhibition of apoptosis,
142 activation of mTOR and
RhoA,
143 and activation of phospholipase A2
144 and produc-
tion of eicosanoids
145 and lipid droplets.
146
Themostprevalent phosphosphingolipid inmost mammalian
tissues(andlipoproteins)isSM,anditschainlengthdiversityhas
already been mentioned with respect to the ∼100 molecular
subspecies in human plasma.
40 Besides its well-known mem-
brane properties,
147,148 it has been suggested that the N-acyl
chain length aﬀects endocytic traﬃcking of SM.
149 Bacteria
produce a SM-binding protein (Lysenin) that is a pore-forming
toxin
150 that has also been useful in studies of SM-mediated
signal transduction.
151
Mammalsalsoproducesmallamountsofceramidephosphoetha-
nolamines,
152 154 although these are found in more substantial
amounts in other organisms, such as chickens (in liver)
152 and
Drosophila melanogaster.
155 Fungi, plants, and other organisms
have inositol phosphorylceramides and other types of glycopho-
sphosphingolipids, often with novel lipid backbones,
133,156,157
and they have been suggested to have functions in intracellular
processes and cell-to-cell interactions, including between cells of
diﬀerent species in host pathogen interactions.
158
2.3.2. Glycosphingolipids. Mammalian glycosphingolipids
begin with either glucose or galactose attached to the 1-hydroxyl
ofCerviaaβ-glycosidicbond.Inadditiontobeingintermediates
in the biosynthesis of more complex glycosphingolipids, these
monohexosylceramides have also been suggested to have bio-
chemical functions. GlcCer plays a critical role in skin (as a
precursor that is hydrolyzed to skin ceramides to form the
permeability barrier),
55 and is required for intracellular mem-
brane transport,
159,160 cell proliferation and survival,
161 multi-
drug resistance,
162,163 and natural killer T cell functions.
164 In
addition, the levels of GlcCer are altered by a wide spectrum of
diseases, including cardiovascular disease, cancer, diabetes, and
skin disorders.
161 Galactosylceramide (and its sulfated deriva-
tives, termed sulfatides) are major components of myelin and
have been reported to interact with each other by carbohydrate-
carbohydrate interactions, perhaps on apposing surfaces of the
multilayered myelin sheath.
165 Considerable attention has been
given to α-GalCer, with an α-versus the β-glycosidic linkage,
which was originally uncovered in studies using extracts from
sponges and is now synthetically produced as KRN7000, because it
isapotentactivatorofiNKTcellsandpromotesimmunotolerance.
166
It is also of interest that the cytokine profile induced by GalCer has
been found to be affected by the nature of the lipid backbone.
167,168
GalCer are sulfated to produce the acidic glycosphingolipids
referred to as “sulfatides” (GlcCer is also sulfated to 30-sulfo-
Glcβ1Cer, SM4s-Glc in some tissues).
4 3-O-sulfogalactosylcer-
amide (30-sulfo-Galβ1Cer, also called cerebrosulfatide or Gal-
Cer-I
3-sulfate) is a major component of the myelin sheath in the
central and peripheral nervous system, kidney, gastrointestinal
tract and endometrium.
169 Sulfatides are thought to be involved
inneuronalcelldiﬀerentiation,myelinformationandmaintenance,
9
and it has been suggested that sulfatide interacts with GalCer in
myelin through trans-carbohydrate carbohydrate interactions.
165
Sulfatides additionally aﬀect the behavior of macrophages,
170 parti-
cipateinadhesionofleukocytestoselectins,andarethoughttobe
involved in platelet aggregation via P-selectin (with inhibition of6394 dx.doi.org/10.1021/cr2002917 |Chem. Rev. 2011, 111, 6387–6422
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the P-selectin sulfatide interaction leading to a reversal of platelet
aggregation).
171 Other extracellular proteins that have been
foundto bind sulfatides include laminin and thrombospondin
172
andhepatocytegrowthfactor.
173Itshouldalsobeborneinmind,
however, that some of the regulatory functions might be intra-
cellular, because sulfatides bind to the N-terminal domain of
sphingosinekinase2.
174Sulfatidesareelevatedinawiderange of
cancers, including colorectal,
175 hepatocellular,
176 renal,
177 brain,
178
small-cell lung,
179 and ovarian
180 cancers, and are thought
participate in metastasis.
175,181
The major disaccharide (Galβ1 4Glcβ1-ceramide), lactosyl-
ceramide (LacCer), is a critical intermediate in the biosynthesis
ofalloftherootstructurefamiliesofmorecomplexsphingolipids
(Figure 1). LacCer has been proposed to function in cell signal-
ing pathway(s) that aﬀect cell proliferation, adhesion, migration,
angiogenesis, phagocytosis and inﬂammation.
182 185 In human
neutrophils,theSrcfamilykinaseLynappearstobecoupledwith
LacCer-enricheddomainsintheplasmamembranesothatligand
(i.e., microorganism) binding to LacCer activates Lyn, triggering
neutrophil functions, such as superoxide generation and cell
migration.
186 Interestingly, the LacCer must have a very-long-
chain fatty acid (C24:1 or C24:0) in the ceramide moiety,
perhaps because that is necessary for proper membrane inter-
digitation and organization.
186,187 It is also possible that LacCer
participates in glycan glycan interactions with other glyco-
sphingolipids, such as GM3.
188
Oneofthesimplestglycosphingolipids(withthreecarbohydrates)
is ganglioside GM3, Neu5Acα2 3Galβ1 4Glcβ1Cer. A func-
tionforGM3intheregulationofcellproliferationwasuncovered
several decades ago by Hakomori and his colleages, who found
that GM3 inhibits the stimulation of growth by epithelial growth
factor (EGF) via inhibition of the activation of the EGF receptor
tyrosine kinase.
189,190 Subsequent studies revealed that the interac-
tion at the surface appears to be via glycan glycan binding
involving multivalent GlcNAc termini on the EGF receptor,
191
and that the intracellular consequences are prevention of the
autophosphorylation of the intracellular kinase domain and the
allostericstructuraltransitiontoasignalingdimer.
192This(anda
similar ﬁnding that GM1 inhibits growth stimulation by platelet
derived growth factor, PDGF)
193 deﬁned the paradigm for
ganglioside action illustrated in Figure 2, that is, that they not
only help deﬁne the properties of the surface of the plasma
membrane but also interact with surface proteins to modulate
their function. Gangliosides are expressed on essentially all
vertebrate cells, and typically with tissue-selective, and often
developmentally related, proﬁles, that is, with varying types of
headgroups and lipid backbones,
7 and in addition to modulating
the way cells respond to a wide range of growth factors (EGF,
PDGF, VEGF, and others), they interact with glycan-binding
proteins on apposing cells via receptors called Siglecs that function
in cell cell recognition.
7,194 Gangliosides have been found to
regulate natural killer cell cytotoxicity via Siglec-7, myelin-axon
interactions via Siglec-4 (also referred to as myelin-associated
glycoprotein, MAG), and inﬂammation via E-selectin.
7 Some
sialic acid-containing glycosphingolipids are very large, such as
the tri- and tetra-sialosylpoly-N-acetyllactosaminyl gangliosides
of humanplacenta that have>20 residues,
136and mightfunction
to create a surface or barrier with particular biophysical properties.
Theglobo(Gb)andisoglobo(iGb)seriestrihexosylceramides
areabbreviatedGb3andiGb3,respectively.AsshowninFigure1,
they diﬀer only with respect to the terminal glycosidic linkage,
which is α1 4 in Gb3 and α1 3 for iGb3. Gb3 has received
much attention because it accumulates in Fabry’s disease due to
defective α-galactosidase A
195 and because it is bound by (and
receptor for) Shiga toxin,
196 verotoxins and the HIV adhesin
gp120.
10 Interestingly, the lipid backbones Gb3 also have a
substantial eﬀect on the way these proteins behave in cells, and
might be important to the eventual pathogenic outcome.
10 Gb3
is elevated in numerous cancers (colorectal adenoma, Burkitt’s
lymphoma, breast cancer and testicular carcinoma),
197 and a
correlation between Gb3 and metastasis has been seen for
colorectal cancer.
198 The relationships are being explored as a
way for cancer detection and targeting using Shiga toxin.
199,200
The story for iGb3 is less clear because although it stimulates
NKT cells and has been hypothesized to be a natural modulator
ofthem,recentstudieshavefoundthatthehumaniGb3synthase
genecontains several mutations that render itsproductnonfunc-
tional(inconstrasttorat,whereiGb3synthaseisintactandiGb3
is found).
201 Therefore, iGb3 is unlikely to represent a primary
natural ligand for NKT cells in humans and iGb3 itself would be
expected to be recognized by the immune system as a foreign
antigen, whichmightcausehumans torejecttransplanted tissues
from animals that express this gene and iGb3, such as pigs.
201
The ﬁrst compound in the lacto-/neolacto- category, Lc3
(GlcNAcβ1 3Galβ1 4Glcβ1Cer),appears tobeimportantfor
embryonic development and brain morphogenesis because
knockout mice for Lc3 synthase gene display preimplantation
lethality.
202 The animals that are successfully born have reduced
survival and display pleiotropic phenotypic changes, including
dwarﬁsm, fur loss, and obesity.
203
These examples illustrate how disruption of the production of
one category of complex sphingolipids can impact survival and
physiological functions. The reader is referred to the references
already cited and others
204 207 for more information about
additional glycosphingolipid structures and functions. Online
sources that are also useful include: (i) the Consortium for
Functional Glycomics (http://www.functionalglycomics.org/);
(ii) the Complex Carbohydrate Research Center at the Uni-
versity of Georgia (http://www.ccrc.uga.edu/∼moremen/gly-
comics/); (iii) GlycoForum (http://www.glycoforum.gr.jp/);
(iv) the KEGG ontology for glycosyltransferases (http://www.
genome.jp/kegg/glycan/GT.html); and (v) LIPID MAPS
(www.lipidmaps.org).
2.4. Other Types of Compounds
The term lysosphingolipid usually refers to a complex sphin-
golipid without the N-acyl-fatty acid, such as sphingosylpho-
sphocholine (sphingoid base 1-phosphocholines) from SM,
sphingosine-1-β-glucoside or -galactoside (“psychosines”), and
other lyso-glycosphingolipids. Not much is known about the
origins and functions of these compounds, although they have
been found in blood and tissues in varying amounts and tend to
be highly bioactive.
208,209 For example, sphingosylphosphocho-
linedisplaybehaviorsthatmightimplicateitasanimportantlipid
mediator in tissues such as heart, blood vessels, skin, brain, and
immune system.
210 It has also been strongly implicated as a
player in atopic dermatitis
211 via a SM deacylase that also acts on
GlcCer.
212 The accumulation of psychosines was one of the
hypotheses for the unusual cellular and biochemical character-
istics of globoid cell leukodystrophy (Krabbe disease), as has
been discussed.
213
Trace amounts of N-a n dO-methyl-sphingoid bases are some-
times found in mammalian sphingolipids and are thought mostly to
be artifacts of the extraction and handling.
214,215 Nonetheless, a6395 dx.doi.org/10.1021/cr2002917 |Chem. Rev. 2011, 111, 6387–6422
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sphingosine N-methyltransferase activity has been found in
mouse brain,
216 and when mice have been treated with saﬁngol,
themetabolitesincludedtheN-methyl-,N,N-dimethyl-andN,N,
N-trimethyl-derivatives (and methylated sphingosine and sphin-
ganineweredetected);
217therefore,thereisaninvivocapacityto
methylate sphingoid bases.
Sphingolipids have also been found as covalent adducts in the
corniﬁed cell envelope of the skin,
218 220 and yeast have been
found to make glycosylphosphatidylinositol-anchored proteins
with ceramide as the lipid moiety.
221
3. SPHINGOLIPID METABOLIC PATHWAYS
The major focus of this discussion of the sphingolipid meta-
bolic pathways willbetoexplainhow thediﬀerent subspeciesare
produced and, in some cases, how defects in these metabolic
steps result in disease, rather than how the pathways are
regulated, which would be a more monumental task. This begins
with how the sphingoid bases arise since, by deﬁnition, all
sphingolipids are comprised of that backbone. Most organisms
deriveasigniﬁcantportionoftheirsphingoidbasesfromdenovo
biosynthesis because the ﬁrst enzyme of the pathway (serine
palmitoyltranserase) is essential for survival of cells in culture,
from yeast
222 to mammals,
223 unless exogenous sphingoid bases
are provided, and elimination of this enzyme is embryonic lethal
foranimalslarge(i.e.,mammals)
224andsmall(e.g.,fruitﬂies).
225
This requirement appears to be due to the eﬃcient degradation
ofsphingoidbasestakenupbytheintestine(viaphosphorylation
at the 1-hydroxyl then cleavage to a fatty aldehyde and
ethanolamine phosphate),
226 229 which might exist to allow
mammals to be selective in which species are in their
repertoire, since a much wider variety of sphingoid base
structural variants are found in other organisms (and, thus,
in food).
11,230 The fate of dietary sphingolipids warrants
further investigation, nonetheless, when one considers that
humans have been estimated to consume more than one
hundred grams of sphingolipids per year.
230 Furthermore,
dietary sphingolipids have been well established to be pro-
tective against cancers of the intestine
231 236 and other
sites
237in studies of experimental animals, and recent studies
of sphingoid base analogs reveal that some structural variants are
well absorbed, as exempliﬁed by ﬁndings with Enigmol 18,
92 a
synthetic 1-deoxy- analog similar to compounds found in some
foods.
11
3.1. Biosynthesis of the Lipid Moieties de Novo
Approximately one decade after elucidation of the deﬁnitive
structure of sphingosine by Herb Carter and colleagues in
1947,
238 its biosynthesis in vitro was achieved by Brady and co-
workers.
239,240 Another decade later, Braun and Snell
241 and
Stoﬀeletal.
242demonstratedthattheinitialbiochemicalreaction
is the formation of 3-ketosphinganine by condensation of serine
and palmitoyl-CoA followed by rapid reduction of the inter-
mediate ketone to produce sphinganine, if NADPH is also
present; thereby establishing the ﬁrst steps of sphingoid base
biosynthesisdenovo(Figure4).Intheearly1990s,thegenesforthe
enzyme that catalyzes the initial reaction, serine palmitoyltrans-
ferase (SPT), were identiﬁed in yeast (LCB1 and LCB2)
243,244
and soon afterward for mammals (SPTLC1, SPTLC2, and
SPTLC3),
245 247 followed in relatively rapid succession by
discovery of genes for most of the other enzymes ofceramide
biosynthesis (as discussed below). Thus, the major steps for
biosynthesis of the lipid moieties of sphingolipids are now
fairly well mapped out biochemically and genetically, although
additional features will undoubtedly surface over time, as for other
pathways.
3.1.1. Formation of the Sphingoid Base Backbones.
SPT is a pyridoxal 50-phosphate (PLP)-dependent enzyme that
catalyzes the condensation of serine and palmitoyl-CoA (and
other amino acid and fatty acyl-CoA cosubstrates, as will be
discussed later). It is a member of the PLP-dependent α-oxoamine
synthase (POAS) subfamily and, like most POAS members,
shares a conserved motif (T[FL][GTS]K[SAG][FLV]G on
SPT2) that contains an active site Lys that is responsible for
formation of a Schiff’s base with PLP.
248 For most organisms,
249
SPT is comprised of at least two separate polypeptides (and
perhaps higher aggregates)
250 that are located in the membrane
of the endoplasmic reticulum. There is also evidence for SPT
being present in other regions of the cell, such as focal
adhesions
251 and the nucleus (and, interestingly, appearing to
shifttothenucleusinproliferatingcells).
252Intheendoplasmic
reticulum, the active site appears to be oriented toward the
cytoplasm,
253,254 as for the other enzymes of ceramide
biosynthesis.
253 It is likely that SPT interacts with other
regulatory proteins. Yeast SPT requires an additional 10-
kDa peptide for optimum activity,
255 a n da l t h o u g ham a m m a -
lianhomologueofTsc3wasnotfound,
256severalcategoriesof
proteins have been suggested to play a regulatory role for
mammalian SPT, including two small SPT subunits, ssSPTa,
and ssSPTb, that appear to influence the fatty acyl-CoA
selectivity,
257 ER proteins that might enhance Ser utilization
(termed Serinc1 to 5),
258 and ORM1.
259,260 Using tandem-
affinity purification and mass spectrometry) to discover pro-
tein protein interactions, a substantial number of proteins
have been identified as potential LCB2-associated proteins in
Saccharomyces cerevisiae.
261 These proteins are involved in
various biological processes such as vesicle transport, nuclear
import and export, among others. A genome-wide yeast two-
hybrid analysis in Drosophila
262 has suggested that SPT2 may
interact with 13 proteins, which include a proton transporter,
organic cation transporter, hsc-70, and ribosomal proteins,
among others.
Elegant structural and spectroscopic studies have been con-
ducted with SPT from the Gram-negative bacterium Sphingomonas
paucimobilis,
263 265 which is a soluble homodimer with ∼30%
amino acid sequence identity with mammalian SPT1 and SPT2,
266
and Sphingobacterium multivorum.
267,268 These have supported
the general mechanism shown in Figure 5. As for many PLP-
dependent enzymes,
269 the amino acid substrate is covalently
boundtoPLPasaSchiﬀbase24(whichisoftenreferredtoasthe
“external aldimine” versus the “internal aldimine” that is pro-
duced by the enzyme-Lys-PLP Schiﬀ base). Spectroscopic evi-
dence has indicated that there is a structural rearrangement of
this chromophoric species upon binding of the second substrate,
a fatty acyl-CoA. The proposed steps for condensation of the
substrates (Figure 5) are similar to what was deduced decades
ago by isotope kinetics studies
270 and generally occurs with
PAOS family enzymes: deprotonation at Cα of the external
aldimine complex 25 to form a quinonoid intermediate 26 and a
Claisencondensationwiththeacyl-CoAsubstrateandlossoffree
CoASH; this β-ketoacid intermediate 27 is doubly β,γ-unsatu-
ratedand undergoes decarboxylation to form another quinonoid
intermediate 28 that rearranges to acquire a proton to form the
product external aldimine 29 that is released from the enzyme as
3-ketosphinganine 30.6396 dx.doi.org/10.1021/cr2002917 |Chem. Rev. 2011, 111, 6387–6422
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It was once presumed that SPT is speciﬁcf o rL-serine, however,
recent studies of the eﬀects of fumonisin B1 on animals and cells
in culture
67 and of the disease human hereditary sensory neuro-
pathy type 1 (HSN1), which is caused by mutations in SPT,
271 273
havefoundthatwildtype,andespeciallymutant,
68,274 276SPTis
also able to utilize L-alanine and glycine to produce cytotoxic
1-deoxysphinganines and 1-(deoxymethyl)sphinganines, as
shown in Figure 6. Like sphinganine, these “atypical” sphingoid
bases are rapidly N-acylated,
67,277 which might explain why their
production even by wild type SPT had escaped previous notice.
Studies of one of the disease-causing mutations (C133W in
SPTLC1)
276 indicate that the wild-typeand mutant enzymes are
notalteredinserineutilizationandhavesimilarapparentbinding
aﬃnities for alanine, but the C133W mutation appears to
enhancethecondensationofalaninewiththeacyl-CoAsubstrate.
It is very intriguing that SPT (even wild-type SPT)
67 is able to
utilize this ensemble of metabolically interrelated substrates,
Ser and Gly are interconverted via serine hydroxymethyltrans-
ferase,andSeriscatabolizedtopyruvate (aprecursorforAla)via
serine dehydratase,
278 at a crossroad of major metabolic path-
ways, which include glycolysis, amino acid metabolism, lipid
metabolism and one-carbon metabolism (with implications for
Figure 4. De novo sphingolipid biosynthesis through lactosylceramide and sulfatide. Starting at top left, serine and palmitoyl-CoA are condensed by
serinepalmitoyltransferase(SPT)toform3-ketosphinganinethatisreducedtosphinganine,whichisN-acylatedbyceramidesynthases(CerS)withthe
shown fatty acyl-CoA preferences, or phosphorylated by sphingosine kinase (SphK). The N-acylsphinganines (dihydroceramides, DHCer) can be
incorporated into more complex dihydro-sphingomyelins, SM, from sphingomyelin synthases, SMS; -ceramide 1-phosphates, CerP, from ceramide
kinase,CERK;-glucosylceramides, GlcCer,fromGlcCersynthase;and-galactosylceramides,GalCer,fromGalCersynthase).DHCerisalsooxidizedto
Cerbydihydroceramidedesaturase(DES1andDES2;DES2isalsocapableofhydroxylatingthe4-positiontoform4-hydroxydihydroceramides, t18:0)
and incorporated into more complex sphingolipids as shown. The diagram also displays the formation of lactosylceramide (LacCer) from GlcCer and
sulfatides(ST)fromGalCer,andtheturnoverofDHCertosphinganine(andCertosphingosine),whichcanberecycledorphosphorylatedandcleaved
to fatty aldehydes and ethanolamine phosphate. Not shown is ceramide phosphoethanolamine, which is present in mammalian cells in nearly trace
amounts.Thekeyisshownatthebottom,andisthesameasforFigure1exceptthatheavyblackboxesrepresentSM,thinblackforCer1P,and(DH)Cer
are represented by the green octagon.6397 dx.doi.org/10.1021/cr2002917 |Chem. Rev. 2011, 111, 6387–6422
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nucleotide biosynthesis) (Figure 6). Thus, many factors might
aﬀecttheiramountsand,indeed,elevatedproductionof1-deoxy-
sphingolipids has recently been proposed to play a role in
diabetes.
279Inanothercontext, thesecompoundsappear tohave
beneﬁcialfunctionsasananti-cancercompound
280thathasbeen
evaluated not only with cancer cells in culture
281 but also by
phase I clinical trials.
94,282 Surprisingly high dosages were
tolerated in the trials, although the reported side eﬀects included
a case of peripheral motor and sensory neuropathy.
94
SPTalsobinds D-serineasacompetitiveinhibitorwithanIC50
of ∼0.3 mM (which is similar to the Km for L-serine),
256,283
but does not appear to be utilized as a substrate. D-serine is
found in plasma
284,285 and urine,
286 and has been shown to
be nephrotoxic,
287 so inhibition of SPT by D-serine might
occur under some in vivo circumstances.
As implied by its name, SPT is usually most active with
palmitoyl-CoA (C16:0-) as the cosubstrate, but it can accom-
modatefattyacyl-CoAsthatarelongerandshorterbyonecarbon
fairly well,
248,256 but these are usually much less prevalent than
palmitoyl-CoA in mammalian cells.
288 These factors probably
account for the high proportions of 18-carbon-chain-length
sphingoid bases in most mammalian sphingolipids. It appears
that another SPT isoform (SPTLC3) has a preference for
myristoyl-CoA (C14)
289 and the amounts of C16-sphingoid
basesaremoresubstantialwhenthisSPTisoformisexpressed.
290
Suchshorterchainlengthsphingoidbasesarecommonininsects
such as Drosophila, which contain C14- and 16-sphingoid bases
and diﬀer in regions of SPT that might account for this
diﬀerence.
291,292 C20-sphingoid bases are found in human
gangliosides,
293 and it is not clear why or how they are elevated
although the production of C20-sphingoid bases might be
determined by expression of ssSPTb.
257 Interestingly, in yeast,
C20-sphingoid bases are elevated under certain stages of growth
andstress,andarethoughttohaverolesincellsignaling.
99Enhanced
denovobiosynthesisof sphingolipids when cells aretreated with
palmitate
294 might link this pathway and the lipotoxicity of this
fatty acid for many cell types,
295 and perhaps through elevated
sphingosine 1-phosphate.
296
SPT is potently and selectively inhibited by several naturally
occurring compounds,
81,297 299 such as myriocin (ISP-1) 14
(which has obvious structural similarity to active site intermediates)
Figure5. Proposedreactionmechanismforserinepalmitoyltransferase(modiﬁedfromD.J.Campopianoandcolleagues,
263 265seetext).Startingwith
theenzymewithpyridoxal50-phosphate(PLP)boundasaSchiﬀ’sbasewithanactivesiteLys(upperleft),Serisboundtomaketheexternalaldimine24
then palmitoyl-CoA is bound and the reaction proceeds as shown until 3-ketosphinganine 30 is released.
Figure 6. Comparison of the structures of the “typical” and “atypical”
sphingoid bases and the interrelationships between intermediary meta-
bolismandtheprecursorsubstratesforthem.TheinterconversionofSer
and Gly are catalyzed by serine hydroxymethyltransferase, and Ser is
convertedtopyruvatebyserinedehydratase.Ser,Ala,andGlyarerelated
to other metabolic pathways as illustrated, and produce the shown
sphingoid bases when utilized by serine palmitoyltransferase.6398 dx.doi.org/10.1021/cr2002917 |Chem. Rev. 2011, 111, 6387–6422
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(Figure 4), sphingofungins, lipoxamycin (neoenactin M1), and
sulfamisterin, as well as by viridiofungins, which are also potent
but additionally inhibit squalene synthase.
300 Aswouldbepredicted
for an enzyme that utilizes PLP as a cofactor, SPT is inhibited by
compounds such as β-chloro-L-alanine
301 and cycloserine,
265
and O-tert-butyl-L-serine methyl ester hydrochloride has also
been reported to be inhibitory.
302 These inhibitors have been
quite useful in studies of the roles of de novo synthesized
sphingolipids in normal and abnormal cell functions, as has a
mammalian cell line (CHO-LY-B cells)
303 that cannot make
sphingoid bases due to loss of catalytic activity due to a G246R
transformation in SPT1,
304 and knockout mice.
305
After establishment of the chain length and subcategory of
sphingoid base (i.e., traditional sphingoid base type versus
1-deoxy- or 1-(desoxymethyl)-sphingoid base), further modiﬁ-
cations, such as introduction of the 4,5-trans double bond of
sphingosine and the 4-hydroxylgroup of 4-hydroxysphinganine
(phytosphingosine) generally take place after the 3-keto-sphin-
goid base has been reduced by an NADPH-dependentreductase
306
and N-acylated, as described in the following sections.
3.1.2. Ceramide Synthases. As shown in Figure 4, sphinga-
nine is at the next key branchpoint in the pathway, where it is
either acylated to different dihydroceramides by a family of Cer
synthases (CerS)
307,308 or phosphorylated to sphinganine 1-phos-
phate by sphingosine kinase(s).
309,310
The ﬁrst genes coding for Cer synthases (CerS), Lag1p and
Lac1p, were found in Saccharomyces cerevisiae,
311,312 followed by
identiﬁcation of a lower molecular weight protein that is also
requiredforactivity.
313Soonthereafter,mammalianhomologues
of Lag1p were characterized and the ﬁrst cloned CerS (originally
calledlass1,andnowreferredtoasCerS1)wasfoundtobehighly
selective for stearoyl-CoA and to make C18-(DH)Cer.
314 This
was followed by characterization of ﬁve additional CerS with
distinct substrate selectivities (summarized in Figure 4) and
other features, such as relative mRNA expression level and tissue
distribution, that were consistent with the types of ceramides
found in the respective source.
307,308,314 319
CerS1 has been found to have an additional mode of regula-
tion in that it is turned over rapidly under basal conditions, and
even more rapidly under stress from agents such as UV light and
chemotherapeutic drugs.
320 Turnover of CerS1 proceeds via
ubiquitination and proteasomal processing, with translocation
from the endoplasmic reticulum to the Golgi apparatus.
321 The
subcellular localization of CerS1 might explain why administra-
tion of exogenous sphingosine to cells in culture disproportio-
nately elevates C18-Cer.
309 Ogretmen and co-workers
322 have
discovered that head and neck tumors have lower CerS1 and
lower proportions of C18-Cer than neighboring normal tissue
(consistent with the substrate speciﬁcity of CerS1 for C18-fatty
acyl-CoA, asshown inFigure4). Inaddition, decreasedC18-Cer
levels were signiﬁcantly associated with the higher incidences of
lymphovascular invasion, pathologic nodal metastasis, and the
overall stage of the primary tumors.
323 These correlations were
shown to have functional consequences by transfection of the
CerS1 gene into head and neck tumor cells in culture, which
restored the levels of C18-Cer and suppressed cell growth.
322
Therefore, CerS1 and C18-Cer appear to play important roles in
the pathogenesis or progression of head and neck cancer. C18-
Cer has been reported to result in repression of the hTERT
promoter via deacetylation of Sp3 by histone deacetylase 1
(HDAC1) in A549 human lung adenocarcinoma cells.
324 Up-
regulation of CerS1 has also been suggested to participate in the
induction of apoptosis in chronic myeloid leukemia cells by
dasatinib.
325 Studies of two mouse strains, ﬂincher and toppler,
withspontaneousrecessivemutationsthatcausecerebellarataxia
and Purkinje cell degeneration have found that the mutations
reside in the CerS1 gene, resulting in complete loss of CerS1
catalytic activity.
326 In addition to Purkinje cell death, there was
also accumulation of lipofuscin, which is common with aging
and in some neurodegenerative diseases, thus, might implicate
CerS1/C18-Cer in these processes.
324
CerS2 mRNA is found at the highest level of all CerS and has
the broadest tissue distribution. It prefers the longer chain fatty
acyl-CoAs, as shown in Figure 4, and there is a good correlation
between CerS2 mRNA levels and the prevalence of those acyl
chains in ceramide and sphingomyelin. Interestingly, CerS2 has
an S1P receptor-like motif that raises the possibility that the
activity of CerS2 mightbe regulated by S1P.
327CerS2 isthe only
CerS for which there is currently a knockout mouse.
328 330 The
mice were essentially devoid of very-long-chain (C22 and C24)-
Cer and downstream sphingolipids, which is also consistent with
the substrate speciﬁcity of CerS2 toward these chain length fatty
acyl-CoAs (Figure 4). Apparently as compensation for the lower
very-long-chain sphingolipids, C16-Cer-sphingolipids were ele-
vated, and diﬀerences were observed in the biophysical proper-
ties of lipid extracts isolated from liver microsomes, with
membranes from CerS2 null mice displaying higher membrane
ﬂuidity and diﬀerences in morphology. As part of the “sphingo-
lipidomic”analysisofthesemicebyourlab,
329,330wediscoveredthat
sphinganine was elevated, by up to 50-fold, which was reminiscent
toinhibitionofceramidesynthasebyfumonisins.
80Thiswasstriking
because,asoccurswhenmiceareexposedtofumonisins,theliversof
the CerS2-knockout mice developed severe hepatopathy from
about 30 days of age, and displayed increased rates of hepatocyte
apoptosis and proliferation progressing to hepatomegaly and non-
invasive hepatocellular carcinoma later in life.
330 These data suggest
that CerS2 is important for the synthesis of dihydroceramide and
preventionofthe accumulationofsphinganine.It alsoappearstobe
particularly important for synthesis of myelin sphingolipids
331
because the mice displayed encephalopathy, which may be largely
because of reduced galactosylceramide levels.
332 CerS2 mRNA
expression has been noted to be signiﬁcantly elevated in breast
cancer tissue compared to paired normal tissue.
333
CerS3isparticularlyimportantinepidermalkeratinocytesand
male germ cells, which produce large amounts of sphingolipids
with very-long-chain- (C26 C36) Cer.
334 Its expression in
keratinocytes increases upon diﬀerentiation, and it can produce
2-hydroxy-Cer, which are common in the epidermis.
335 Studies
of mouse embryonic stem cells and embryoid bodies have found
that the latter have higher CerS3 mRNA and higher proportions
of C18-, C24- and C26-, and less C16-dihydroceramides.
336
Treatment of a mantle cell lymphoma cell line (Rec-1) with the
endocannabinoid analogue R(+)-methanandamide has been
reportedtoincreaseC16-,C18-,C24-,andC24:1-Cerandfound
transcriptional induction of CerS3.
337 All of these are consistent
with the fatty acyl-CoA selectivity for CerS3 shown in Figure 4.
CerS4 has been studied less than the other CerS, perhaps in part
because the Cer subspecies that it makes (C20 (2c a r b o n s )
315 are
not prevalent in most sphingolipids. It is expressed at highest levels
in skin, leukocytes, heart, and liver.
327 Studies with a pancreatic
beta-cell model, INS-1 beta-cells, found that supplementation of
the medium with high glucose and palmitate increased CerS4.
338
CerS5 and CerS6 are often considered in concert since both
make C16-Cer, with CerS6 also utilizing myristoyl-CoA to make6399 dx.doi.org/10.1021/cr2002917 |Chem. Rev. 2011, 111, 6387–6422
Chemical Reviews REVIEW
C14-Cer, as shown in Figure 4. CerS5 was the ﬁrst mammalian
CerS that was puriﬁed and proven to be a genuine synthase for
ceramide.
317 Co-immunoprecipitation studies suggest that
CerS2, 5, and 6 might exist as heterocomplexes in HeLa
cells.
339 A number of factors induce CerS5 and CerS6, such
asdevelopment,
340ionizingradiation,
339thecyclooxygenase-2
(COX-2) inhibitor celecoxib,
341 and the death receptor ligand
TRAIL (tumor necrosis factor-related apoptosis-inducing
ligand).
342
Despite having diﬀerences in fatty acyl-CoA-speciﬁcity, the
CerS have similar apparent Km toward the sphingoid base
substrate sphinganine (ranging from 2 to 5 μM).
343 This implies
thatassphinganineismadedenovo,itspartitioningintodiﬀerent
categoriesof(dihydro)Cer willbegoverned bytherelativelevels
of the CerS in its vicinity. This has fairly consistently been
supported by the studies described above, where particular CerS
were varied in amount in relationship to the other isozymes, and
by a study by Obeid and co-workers
344 where individual CerS
were suppressed in MCF-7 cells using small-interfering RNA
(siRNA).
344 As was seen in the CerS2 knockdown mouse,
329,330
elimination of one CerS often resulted in counter-regulation of
one or more of the other CerS and corresponding shifts in the
chain lengths of the cellular ceramides such that overall levels of
complex sphingolipids were generally maintained despite reduc-
tion of a particular CerS (however, free sphinganine was not
elevated in the siRNA studies).
344 It is not clear if the compo-
nents of this pathway are present in the ER as discrete polypep-
tides that release their productsinto the ER membrane to diﬀuse
to the next enzyme, or if there are macromolecular complexes
that position the active sites so the product of one enzyme is
released near the active site for the next enzyme. There isprecedent
for this latter scenario in recent ﬁndings with ELOVL1, a fatty
acyl-CoAelongasethatisessentialforproductionofverylong-chain
fatty acids that are usedby CerS2.
345 This might also account for
theelevationofsphinganineintheCerS2knockoutmouse.
329,330
There are a large number of naturally occurring inhibitors of
CerS,
11 with the best characterized (because of their public
health relevance) being the fumonisins, a family of mycotoxins
produced by Fusarium verticillioides
346 that cause a wide range of
diseases of agriculture animals (equine leukoencephalomalacia
and porcine pulmonary edema) and humans (cancer and birth
defects).
79,347 The structure of fumonisin B1 13 and the char-
acteristics of the inhibition suggest that the aminopentol back-
bone competes for binding of the sphingoid base substrate,
whereastheanionictricarballylicacidsmayinterferewithbinding
of the fatty acyl-CoA.
348 Inhibition of what appears to be all
CerS (based on complete blockage of de novo sphingolipid
biosynthesis) is accompanied by dramatic elevations in sphinga-
nine and sphinganine 1-phosphate at early times, later elevation
of sphingosine and S1P (from blockage of reutilization of
the backbones of sphingolipids that are turning over), and
depletion of complex sphingolipids --all of which are likely to
contribute to fumonisin toxicity, carcinogenicity
348,349 and
teratogenicity.
79,350 There is also an intriguing interplay between
TNFα and fumonisins
351 353 which might be related to the
ability of cytokines to aﬀect sphingolipid biosynthesis and
turnover.
354 356Somewhatparadoxically, butof possible clinical
importance, treatment with fumonisin B1 has been found to
signiﬁcantly reduce the systemic toxicity, weight loss, and morta-
lity of zymosan-induced nonseptic shock in mice.
357
Cer can also be made by reversal of acid ceramidase with a strict
stereochemical requirement for D-erythro-sphingosine,
358,359
D-erythro-sphinganine, and D-erythro-phytosphingosine but can
occur with a wide spectrum of fatty acids, including both
saturatedandunsaturatedfattyacids
358andchainlengthsvarying
from C8 to C22.
359 Detergents, pH, and various lipids, such as
cardiolipin, phosphatidylcholine, and lysophosphatidylcholine
can aﬀect the hydrolysis reverse activity of ceramidases.
359 This
appears to contribute little to Cer synthesis in vivo (as discussed
above), however, recent ﬁndings with neutral ceramidase-
deﬁcient mice indicate that it might play a role in ceramide
formation in mitochondria.
360
N-acetyl-sphingosine (C2-Cer) and -sphinganine (C2-DHCer)
have been reported to be made by a platelet-activating factor
(PAF)-dependent transacetylase
361 that is widely distributed
amongtissuesand appearsto bemoreactivewithsphingosine
than sphinganine.
106 This transacetylase is a multifunctional
enzymewiththreecatalyticactivities(lysophospholipidtrans-
acetylase, sphingosine transacetylase, and acetylhydrolase)
anditsregulationdiﬀersformacrophagescompared tomono-
cytes.
362 C2-DHCer has also been found in cells and animals
treated with fumonisin B1 (as well as the untreated controls),
348
butitisnotclearifthisisproducedbythePAFtransacetylase
or a more generic acetyltransferase used in detoxiﬁcation of
xenobiotics.
3.1.3. Desaturation and Hydroxylation of Dihydrocer-
amide to Form Ceramides and 4-Hydroxyceramides
(Phytoceramides). Ong and Brady first suggested that incor-
poration of the 4,5-trans-double bond of sphingosine occurrs at
theDHCerlevel
363asshowninFigure4,butthiswasignoredfor
many years by textbooks (and even today by metabolic pathway
wall charts) that showed direct conversion of sphinganine to
sphingosine. Desaturation at the DHCer level in vivo was
established conclusively by pulse chase labeling studies,
294
and confirmed by development of an in vitro assay for this
highlylabileenzyme.
364DHCerdesaturaseswerethencloned
from plants,
365,366 leading to the subsequent identification
of the desaturase genes from many organisms, including
humans.
367 370 The two mammalian desaturases, DES1 and
DES2, appear to have different functions, for DES1 to add
the 4,5-trans double bond to make Cer,
367 and DES2 to
hydroxylate DHCer at position 4 to produce the t18:0 backbone
of phytoceramides.
368 370
DES activity is inﬂuenced by the alkyl chain length of the
sphingoid base and fatty acid, the stereochemistry of the sphin-
goidbase(D-erythroversus L-threo-dihydroceramides),thenature
of headgroup, and the ability to utilize alternative reductants.
364
Introductionofthe4,5-doublebondcanbeanalyzedusingNBD-
DHCer, which reveals interesting features about the stereose-
lectivityofthereactionandsubsequentmetabolism.
371DES1isa
myristoylated protein and its activity appears to be aﬀected by this
post-translational modiﬁcation.
372
DES plays a very important role in cell regulation because the
signaling targets of Cer typically are not aﬀected by comparable
levels of DHCer, which is a sensible mechanism to minimize
accidentalinduction ofapoptosisbythisintermediate ofdenovo
sphingolipid biosynthesis.
108 DHCer are bioactive, nonetheless,
as inducers of autophagy, which surfaced in studies of the6400 dx.doi.org/10.1021/cr2002917 |Chem. Rev. 2011, 111, 6387–6422
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mechanisms of action of the anticancer drug fenretinide
(4-hydroxyphenyl retinamide, 4HPR) 31.
97 Fenretinide had
been thought previously to elevate Cer in studies of how this
compoundwastoxicfornumeroushumancancercelllines,
373,374
both as an inducer of SPT and ceramide synthase.
375 However,
when examined by mass spectrometry, the accumulating “Cer”
was found to be DHCer, and fenretinide was deduced to inhibit
DES,
97 which has been subsequently conﬁrmed.
376 The sphin-
golipidomic studies that uncovered this novel mechanism of
action of fenretinide also revealed that this agent elevated
sphingoid bases and sphingoid base 1-phosphates,
97 which have
the potential to mediate, or suppress, cancer cell killing, respec-
tively; therefore, follow-up studies examined whether coadmi-
nistration of a sphingosine kinase inhibitor would enhance the
toxicity of fenretinide, and this was found to be the case.
377
Likewise,knockdownofceramidasehasthepotentialtodecrease
theproductionoffreesphingoidbasesandamelioratethetoxicity
of fenretinide, and this too has been found.
378 A large number of
inhibitors speciﬁcally targeted to DES have also been prepared
and characterized.
379 383
A number of physiological factors have also been found to
modulate DES. For example, palmitate (but not oleate) in-
creased mRNA encoding DES1 and Cer biosynthesis,
384 and
oxidative stress decreaseddihydroceramidedesaturase activity in
atime-anddose-dependentfashion(andelevatedDHCer).
385A
recent comparison of breast cancer cell lines noted that they
diﬀered in the relative expression levels of DES1 versus DES2,
and follow-up analysis of the sphingolipids of the cells found
the correlating diﬀerences in Cer versus PhytoCer in the
sphingolipids.
290
The enzymes and genes have not yet been identiﬁed for the
production of the mammalian sphingoid bases with a second
double bond at carbon 14, or for the skin sphingoid base with a
hydroxyl at position 6.
3.2. Complex Sphingolipid Biosynthesis
Inmammals,Cer isatthebranchpointforbiosynthesisoffour
major compounds (Figures 4 and 7): the two phosphosphingo-
lipids, sphingomyelin (SM) and Cer 1-phosphate (Cer-P) and
two glycosphingolipids, galactosylceramide (GalCer) and gluco-
sylceramide (GlcCer), which are converted into hundreds of
complex glycosphingolipids as discussed above and summarized
in an excellent review by Furukawa and colleagues,
386 a compre-
hensive series of pathway maps prepared by Akemi Suzuki,
387
a web-based hypothetical pathway scheme (www.sphingo-
map.com),andthisreview.Pathwaymapsbasedontheknown
genes for these pathways have also been developed for use
with gene expression data sets.
290,388 In addition, two more
headgroups have been found to be produced by mammals,
ceramide phosphoethanolamine
153 and 1-O-acylceramide,
389
butin such smallamounts that they have not been included in
Figure 4 or 7.
3.2.1. Sphingomyelin,CeramidePhosphoethanolamine,
and Ceramide Phosphate. Cer is metabolized to SM in the
Golgi
390,391 and plasma membrane
392,393 by SM synthases that
catalyze the transfer of phosphorylcholine from phosphatidyl-
choline to the 1-hydroxyl of Cer with the liberation of dia-
cylglycerol,
394,395 with SMS1 localized to the Golgi, and SMS2
localized to the plasma membrane.
396 Because SM biosynthesis
occurs at multiple sites and by more than one enzyme, as well as
involves trafficking of the precursor Cer by more than one
mechanism, it can be a difficult process to study.
397 This is
probably also a manifestation of the multiple roles that these
metabolites (SM, Cer and diacylglycerols) play in plasma
membrane signaling.
27 A substantial number of studies have
explored the biosynthesis and turnover of SM in cell signaling
and disease, as reviewed recently by Hannun and colleagues.
27,28,31
A useful tool in studies of SM synthesis has been the inhibitor
D609 32.
398
SMS2 knockout and SMS2 liver-speciﬁc transgenic mice
have been prepared
399 a n db o t hh a dl o w e rp l a s m aS Mt h a n
wild-type mice under usual dietary conditions, but diﬀered
w h e nf e dw i t hh i g hf a td i e t s .
399 The SMS2 knockout mouse
has also shown attenuated lung injury in response to lipopoly-
saccharide
400andreducedatherogenesis,
401amongotherinter-
esting phenotypes.
Ceramide phosphoethanolamine biosynthesis involves the
analogous transfer of the phosphoethanolamine group from
phosphatidylethanolamine to Cer, which was ﬁrst noted with
microsomes and plasma membranes from rat brain and
liver
393 (also with subsequent methylation using S-adenosyl-
methionine to produce SM).
402 The enzymes responsible
for ceramide phosphoethanolamine biosynthesis have been
reported to be a speciﬁc transferase, SMSr, that has only
ceramide phosphoethanolaminesynthase activity,andSMS2,
which appears to be bifunctional enzyme that synthesizes
both SM and ceramide phosphoethanolamine.
153 SMSr
catalyzes the synthesis of ceramide phosphoethanolamine in
the lumen of the endoplasmic reticulum, but in only trace
amounts, and has been speculated to play a role in Cer
homeostasis because blocking its catalytic activity causes a
substantial rise in Cer.
154
The other phosphosphingolipid made by mammals is cera-
mide 1-phosphate, which is produced by ceramide kinase
(CERK) and possibly other yet-to-be-discovered enzymes be-
cause CERK knockout does not completely eliminate these
compounds.
403 CERK is selective for Cer with a minimum fatty
acyl chain length of 12 carbons, and the 4,5-trans double bond
of the sphingoid base backbone is important for substrate
recognition.
404 The production of ceramide 1-phosphate has
been implicated in cell proliferation and survival,
405 and activa-
tionofthecytosolicphospholipaseA2(cPLA2)forinﬂammatory
signaling.
406 KNVP-231 33 is a speciﬁc and reversible CerK
inhibitor that is active in the low nanomolar range and useful in
studies of this metabolic step.
407
One of the factors that governs the biosynthesis of both SM
andCer1PisthedeliveryofCertotheenzymebyaCertransport
protein (CERT) discovered by Hanada and co-workers.
408,409
CERT mediates the ER-to-Golgi traﬃcking of ceramide,
410 and
appearstoactatmembranecontactsitesbetweentheERandthe
Golgi apparatus.
411
CERT most eﬃciently transfers Cer having C14- to C20-
chain lengths (but not longer alkyl chains) as well as6401 dx.doi.org/10.1021/cr2002917 |Chem. Rev. 2011, 111, 6387–6422
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C16-dihydro- and phyto-Cer.
412 N-(3-Hydroxy-1-hydroxymethyl-
3-phenylpropyl)dodecanamide (HPA-12 34) (see comment on
stereochemistry)
413 inhibits ceramide traﬃcking by CERT.
414
3.2.2. Other Non-Glycan Headgroups. The other known
category of nonglycan headgroup modification by mammals is
O-acylation,
389 which has been shown to be due to a group XV
calcium-dependent, lysosomal phospholipase A that has the
unique ability to transacylate short chain ceramides. It is highly
expressedinalveolarmacrophages,andmicelackingthisenzyme
develop a phenotype similar to human autoimmune disease.
415
3.2.3. Glycosphingolipids. The core concepts for how cells
biosynthesize hundreds of different headgroup categories of
glycosphingolipids are summarized in Figures 7 and 8. Basically,
the stage is set by there being a limited number of initial
glycosyltransferases (mammals only add glucose and galactose
directly to Cer even though several other types of carbohydrates
are utilized later), followed by one major product from GlcCer
(addition of Gal to form LacCer), then generation of further
diversity by expansion to the root structure categories summarized
inFigure1.TheGalaseries(i.e.,fromGalCer)issimpler,althoughit
contains somewhat more components than are illustrated in
Figure7(suchasthesulfatedglucuronoglycolipids,whichwillbe
described later).
Glycosphingolipid biosynthesis (and especially ganglioside
biosynthesis) has been referred to as a “combinatorial” process
14
because it produces many products from relatively few reactions
(catalyzed by the glycosyltransferases) that are able to utilize a
toolkit of precursors and intermediates to produce an ensemble
of products. To a certain degree, the nature of the products are
predictable based on the speciﬁcities of the enzymes, their
locations, and the localization, amounts and types of the cosub-
strates; however, since most of the components are membrane
associated, all possibilities are not necessarily produced in
detectable amounts.
The glycosyltransferases often transfer a speciﬁc carbohydrate
fromtheappropriate sugar nucleotide (e.g.,UDP-Glc,UDP-Gal,
CMP-sialic acid) to a speciﬁc position on a particular type of
acceptor (Cer or to the nonreducing end of the growing carbohy-
dratechain attached to Cer). For most of the enzymes presented
inthisreview,sphingolipidsarethepreferredacceptors.
386Inlarge
part, the structure feature of the acceptor that is recognized is the
carbohydrate portion, however, there are instances where the
backbonehasbeennotedtobeafactor,suchasinthepartitioning
of α-hydroxy-Cer into downstream glycosphingolipids.
416
Figure 7. A scheme depicting the major headgroup additions to (dihydro)ceramides and subsequent metabolites that deﬁne the diﬀerent categories
(including root structure series) of more complex sphingolipids. Ceramides and dihydroceramides (one of which is depicted in the octagon at one
o’clock in this diagram) are converted into sphingomyelin (SM), ceramide 1-phosphate (CerP), glucosylceramide (GlcCer), and galactosylceramide
(GalCer), then to downstream metabolites as shown (see text). Ceramide phosphoethanolamine and 1-O-acyl-ceramides are not shown because they
appearinmammaliancellsintraceamounts.Eachenclosedsectionrepresentsasubcategoryofglycosphingolipid,suchasSTforsulfatides(redcircles,as
inFigure4)(notethatsomeofthesulfatedglycosphingolipidsfallintoboththeGalCer,thatis,Gala,subcategoryandothersarederivativesofGlcCer).
Thearrow totheisoglobofamilyislessboldbecausethatenzymeisnotthoughttobeactiveinhumans.Thekeyforthesymbolsandcoloringschemeis
the same as in Figure 1 the earlier ﬁgures.6402 dx.doi.org/10.1021/cr2002917 |Chem. Rev. 2011, 111, 6387–6422
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3.2.3.1. Biosynthesis of GlcCer. GlcCer are synthesized by
UDP-Glc:Cer glucosyltransferase (alternatively called GlcCer
synthase and abbreviated GCS, UGCG and CGlcT-1),
417 and
the only mechanism to produce GlcCer appears to be via this
gene product based on studies with a mouse melanoma cell line
(GM-95 cells) with mutated GCS.
418 Studies with this cell line
have been very informative about the effects of eliminating
GlcCer and downstream glycosphingolipids, which slowed their
growth rate and altered cell morphology,
418 although the cells
retained the ability to adhere to extracellular matrix (ECM)
proteins such as fibronectin, collagen, and laminin.
419 Elimina-
tion of this enzyme in mice with a null mutation
420 was
embryonic lethal, but embryogenesis proceeded well into gas-
trulation with differentiation into primitive germ layers and
patterning of the embryo before death.
GlcCer biosynthesis can be blocked by inhibitors of this
enzyme,
421 and when applied to mouse knockout model of
Fabry disease (where a deﬁciency of the enzyme α-galactosidase
causes Gb3 to accumulate), inhibitor treatment blocked accu-
mulationofGb3inthekidney,liver,andheartwithoutsigniﬁcant
changes in body weight or organ weight, which was suggestive
that such compounds might be promising as therapeutic agents
for the treatment of glycosphingolipid storage disorders. The
most recent generation of inhibitors of GlcCer synthase is
(1R,2R)-nonanoic acid[2-(20,30-dihydro-benzo [1,4] dioxin-60-
yl)-2-hydroxy-1-pyrrolidin-1-ylmethyl-ethyl]-amide-L-tartaric
acid salt (Genz-123346) 35.
422 This compound has also shown
eﬃcacy in mouse models for Fabry disease,
423 Gaucher disease
(where there is accumulation of GlcCer due to defective lysoso-
mal glucocerebrosidase/acid β-glucosidase),
424 and polycystic
kidney disease, a family of genetic disorders characterized by
renal cystic growth and progression to kidney failure.
425
Use of GlcCer synthase inhibitors has revealed how decreases
in cellular levels of neutral glycosphingolipids and gangliosides
(andelevationofCer)causescellcyclearrest,
426andhowGlcCer
synthesis appears to be a major determinant of survival of tumor
cells.
427,428 They also led to identiﬁcation of a previously
unknown pathway for ceramide metabolism, the formation of
1-O-acylceramide via a phospholipase A2.
415,429
3.2.3.2.BiosynthesisofLacCer.GlcCerisnextglycosylatedto
Galβ1 4Glcβ1Cer (LacCer) by two LacCer synthases (β4-
galactosyltransferases), β4GalT-V and -VI,
430 with the former
also being implicated in the synthesis of N-glycans of cell surface
glycoproteins.
183 Before this can occur, however, the GlcCer
mustfliptotheinsideoftheGolgibecauseGlcCerismadeonthe
cytosolic aspect of the ER or early Golgi membranes,
431,432
whereas LacCer and more complex glycosphingolipids are made
in the lumen of the Golgi apparatus.
433 Studies with rat liver ER
and Golgi membranes have foundthattransbilayer movement of
spin-labeled GlcCer is rapid, saturable, and inhibitable by pro-
tease treatment, which suggests that the membranes contain a
GlcCerflippase.
434ThemechanicsofGlcCerdeliverytothesites
Figure8. Representativereactionsofgangliosidebiosynthesis.Anillustrationofthe“combinatorial”natureofgangliosidebiosynthesisbytheindicated
glycosyltransferases (note alternatives names for each enzyme). The key is the same as in Figure 1.6403 dx.doi.org/10.1021/cr2002917 |Chem. Rev. 2011, 111, 6387–6422
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of higher glycolipid biosynthesis appears to be more complex
than just flipping across the membrane because after GlcCer is
made on the cytosolic leaflet of the Golgi, it is transported back
intotheER(viaGolgi-associatedfour-phosphateadaptorprotein
2, FAPP2) before achieving access to the lumen of the
Golgi.
435,436 FAPP2 is a dimeric protein that has the capability
to form tubules from membrane sheets (an activity that is
dependent on the phosphoinositide-binding activity of the PH
domain of FAPP2) and it has been suggested that FAPP2
functions directly in the formation of apical carriers in the
trans-Golgi network.
437,438
SomeofthefactorsthathavebeenreportedtoregulateLacCer
synthase include growth factors, cytokines, lipids, lipoproteins,
and hemodynamic factors, such as ﬂuid shear stress.
439
3.2.3.3. Biosynthesis of Ganglio-Series Glycosphingolipids.
As shown in Figure 7, one of the fates of LacCer is conversion to
the neutral and acidic members of the ganglio-root structure
series glycosphingolipids (blue bordered box in Figure 7). The
enzyme responsible for the first neutral metabolite Gal-
NAcβ1 4Galβ1 4Glcβ1Cer (GA2, also called asialo-GM2) is
GM2 synthase, which is also called β4GalNAcT, β1,4-N-acet-
ylgalactosylaminyltransferase and GM2/GD2 synthase because
itadditionallyconvertsgangliosidesGM3toGM2,GD3toGD2,
etc., as shown in Figures 7 and 8.
440 Therefore, this enzyme is
critical for synthesis of all complex gangliosides enriched in the
nervous system of vertebrates (GM1a, GD1a, GD1b, GT1b,
GQ1b, etc.), as well as downstream neutral (asialo-) glycosphingo-
lipids (GA1), which has been confirmed by studies with the
knockout mouse.
386,441 Interestingly, knockout of this gene did
not affect brain morphology/histology, but there were effects on
the maintenance and repair of nervous tissues, differentiation of
spermatocytes,andregulation ofinterleukin-2receptorcomplex.
The other major branch of metabolism of LacCer is its
sialylation to ganglioside GM3 (Figures 7 and 8) by ST3Gal-V
(SAT-I, CMP-N-acetyl-neuraminate:lactosylceramide α2,3-sia-
lyltransferase, GM3 Synthase).
442 GM3 null mice are unable to
synthesize GM3, as anticipated, and appear to be without major
abnormalities, but have a greater sensitivity to insulin due to
enhanced insulin receptor phosphorylation in skeletal muscle,
are protected from high-fat diet-induced insulin resistance,
443
and have impaired hearing due to selective degeneration of the
stereocilia of hair cells in the organ of Corti.
444 The relationship
between GM3 and insulin signaling is provocative because it
might provide better insight into type 2 diabetes, and it has been
suggested that this involves interactions between insulin recep-
tors and gangliosides in membrane microdomains, and might be
a new paradigm for insulin receptor regulation.
444 Defects in
GM3 synthase have also been found clinically,
445 wherein a
nonsence mutation in the gene that would cause a premature
termination caused loss of activity, GM3 and its derivatives, and
developmental stagnation and blindness.
The other downstream metabolites in this pathway shown in
Figures 7 and 8 are formed by analogous reactions, for example,
GA2 is converted to GA1 by β3GalT-IV (also called GM1
synthase, β3GalT, and Gal-T2),
446 which can be in turn sialy-
lated to ganglioside GM1b by GT1b/GD1a/GM1b synthase
(also named ST3Gal-II, SAT-IV, CMP-N-acetylneuramininate:
D-galactosyl-N-acetyl-D-galactosaminyl-(N-acetylneuraminyl)-D-
galactoxyl-D-glucosylceramide α2,3-sialyltransferase).
447 Like-
wise,toformthedisialo-(GD3)andtrisialo-(GT3)gangliosides,
the additional enzymes GD3 synthase (SAT-II, ST8Sia-I, CMP-
N-acetylneuraminate: GM3 α2,8-sialyltransferase) and GT3
synthase (SAT-III) are invoked (with the products of each of
these serving as substrates for the enzymes already described to
synthesize GD2, GT2, etc., as shown in Figure 8). Thus, the
proﬁle of ganglio-series glycolipids that are made by a particular
cell will depend on the particular glycosyltransferases that are
expressed, their kinetic properties, and other issues such as
localization, availability of the substrates, presence of enzymes
that may be competing for the same intermediates, and the rates
at which the precursors and products are traﬃcked through the
Golgi.
14 As these relationships become better understood, one
can begin to make computational predictions about what species
will be made based on gene expression proﬁles and pathway
maps,
448andevenpredictionsaboutglycanstructuresfromgenomic
information about glycosyltransferases,
449,450 although the out-
comes still require experimental veriﬁcation.
A reaction not shown in these diagrams is the addition of
fucose to produce compounds such as fucosyl-GM1a shown in
Figure 1. This is catalyzed by fucosyltransferases (α1,2-fucosyl-
transferase 1 and 2, FUT1 and FUT2;
451 α3/4-fucosyltransfer-
ase, FUT3, Lewis enzyme;
452 and others). Fucosyl-GM1, which
canbemadebybothFUT1andFUT2,isexpressedinavarietyof
cancertissues,andhasbeenconsideredtobeatumormarkerand
target for immunotherapy.
453 Aberrant glycosphingolipid pro-
ﬁles are one of the hallmarks of cancer and over forty years ago,
Hakomori and Murakami noted that “the structural remodeling
of glycolipids and glycoproteins are undoubtedly a key to open a
secret box of malignancy.”
454 Largely through the eﬀorts of
Sen-Itiroh Hakomori and his many collalborators and trainees,
455 a
lotisnowknownaboutthelinksbetweenglycosphingolipidsand
abnormal cell behavior in cancer, as well as tumor progression,
metastasis, and invasivity.
456,457 The underlying premise has
been that some of these compounds might be useful biomarkers,
and/or that restoration of a more normal composition might
have clinical beneﬁt. This latter idea has been supported, for
example, by studies of gliomas, which have lower expression of
several sialyltransferases (ST6Gal1, ST6, and ST6GalNAcV), so
when U373MG glioma cells were stably transfected with ST6Gal-
NAcV, this increased expression of GM2α and GM3 gangliosides,
caused marked inhibition of in vitro invasivity, modiﬁed cellular
adhesion to ﬁbronectin and laminin, and inhibited tumor growth
invivo.
458Therefore,theconceptthatnormalizationofsphingolipid
proﬁlesincancercouldbeoftherapeuticbeneﬁtisveryappealing.It
is worth mentioning that the links between cancer and glyco-
sphingolipids have not been limited to the headgroups
459 and this
also might be useful in identifying more unique biomarkers.
Oneother category of ganglioside derivative that is not shown
in these pathway diagrams is the O-acetylation of the Neu5Ac,
which is conducted by a 7- or 9-position sialic acid-speciﬁc
O-acetyltransferase.
460 An enzyme has also been found that
removes the acetyl-group from 9-O-acetyl-sialic acids.
461 There
has been considerable interest in 9-O-acetylGD3 because it is
found in tumors and appears to protect them from apoptosis.
462
Regulation of ganglioside expression has been studied fairly
extensively, particularly during brain development, where gang-
lioside biosynthesis switches between expressing simple and
complex gangliosides or between diﬀerent ganglioside series, and
thefactorsthatgovernthis“orchestrationofglycosyltransferases”
463
have been reviewed.
3.2.3.4. Biosynthesisof Lacto-/Neolacto-Series Glycosphin-
golipids. Biosynthesis of the lacto-/neolacto-series glycosphingoli-
pidsbeginswiththeformationofGlcNAcβ1 3Galβ1 4Glcβ1Cer
(alsoreferredtoasLc3oramino-ceramidetrihexoside,amino-CTH)6404 dx.doi.org/10.1021/cr2002917 |Chem. Rev. 2011, 111, 6387–6422
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by β-1,3-N-acetylglucosaminyltransferase (also named UDP-N-
acetylglucosamine: β-galactose β1,3-N-acetylglucosaminyltrans-
ferase, amino-CTH synthase or β3GlcNAcT) (Figure 7). This
gene has been cloned
464 and the gene named β3Gn-T5. The
knockout mouse displays multiple phenotypic changes with
some dying in less than 2 months, developing early stage growth
retardation, and having shorter lifespan overall. Pathologies
include splenomegaly and notably enlarged lymph nodes, fur
loss, obesity, and reproductive defects.
203
The distinction between the lacto- versus neolacto- series
glycosphingolipids is determined by the next galactosyltrans-
ferases, which are β1,3GalT for Lc4 and β1,4GalT for nLc4
(Figure 7). Lc4 is a precursor for formation of Lewis
a, Lewis
b
upon addition of fucoses, and sialyl Lewis
a (by the action of
ST3Gal-III), and nLc4 is a precursor for Lewis
x, Lewis
y, and
sialyl-Lewis
x (c.f., Figure 2 and Figure 7).
3.2.3.5.BiosynthesisofGlobo-/Isoglobo-SeriesGlycosphin-
golipids. Biosynthesis of the Gb3 (Galα1 4Galβ1 4Glcβ1-
Cer) is catalyzed by Gb3 synthase (α1 4-galactosyltransferase,
α1 4GalT), then to Gb4 (via β3GalNAcT), as shown in
Figure 7. The next globoside in this series, Gb5 (synthesized
by β3GalT-V), is also known as the stage-specific embryonic
antigen-3 (SSEA-3),
465 a frequently used stem cell marker.
466
Although iGb3 synthase (α1 3GalT) is shown in Figure 7 by a
faint line, the human iGb3 synthase gene contains several
mutations that render its product nonfunctional,
201 and this
has been supported by in vitro assays.
197
As noted earlier, globosides have also receivedmuch attention
as receptors for Shiga toxin,
196 verotoxins, and the HIV adhesin
gp120,
10 and for their elevationsin cancer
197and Fabry’sdisease.
195
3.2.3.6. Biosynthesis of GalCer. GalCer are made by UDP-
Gal:Cer galactosyltransferase, also called GalCer synthase or
cerebroside synthase, and abbreviated CGT or CGalT (human
gene,UGT8).
467GalCerissynthesizedinthelumenoftheER
468
using UDP-Gal that is transported to the lumen of the ER by
UDP-Gal transporter 2 (UGT2), a splice variant of UGT1 (the
transporter for UDP-Gal into the Golgi) that contains an ER
locating dilysine motif.
469 Disruption of the mouse gene pro-
duced animals that did not synthesize GalCer or sulfatide but
they formed myelin containing glucocerebroside. This did not
substitute fully for GalCer, however, because the mice exhibited
severe generalized tremoring and mild ataxia, and developed
progressive hindlimb paralysis and extensive vacuolation of the
ventralregionofthespinalcord.
470Transgenicmice overexpressing
the this GalCer synthase had an increase in activity and mono-
galactosyldiglycerideandnonhydroxyfattyacid-containingGalCer,
but the latter was accompanied by a concomitant decrease in
α-hydroxylated GalCer; therefore, there must be some mechanism
to maintain the total level of GalCer. Nonetheless, the transgenic
micedevelopedprogressivehindlimbparalysisanddemyelination.
471
3.2.3.7. Sulfated Glycosphingolipids. Sulfatides are formed
by the transfer of a sulfate to one of the hydroxyls of a glyco-
sphingolipid by using the activated sulfate donor 30-phosphoa-
denosine-50-phosphosulfate (Figure 7). Two of the more
thoroughly studied sulfotransferases are 30-phosphoadenosine
50-phosphosulfate:galactosylceramide sulfotransferase (GalCer
sulfotransferase), which produces 30-sulfo-galactosylCer,
472 and
asulfotransferasefromratbrain
473thatcatalyzesthetransferofsulfate
to glucuronylglycolipids (GGL),
474 such as GlcAβ1 3Galβ1 
4GlcNAcβ1 3Galβl 4Glcβl-Cer to from sulfated glucuronyl-
glycolipids (SGGL), 30-sulfo-GlcAβ1 3Galβ1 4GlcNAcβ1 
3Galβl 4Glcβl-Cer. Mass spectrometry has been helpful in
mapping out the metabolic pathways for sulfatides of the gang-
lio-series.
475AconnectionbetweenvitaminK(orwarfarinadmin-
istration) and sulfatide biosynthesis has been suggested by several
studies, but the mechanism has been elusive.
476
The cDNA encoding GalCer sulfotransferase has been
cloned,
477 and knockout mice have been generated to analyze
the biological roles of sulfoglycolipids and pathophysiology of
their deﬁciency, which included neurological disorders due to
myelin dysfunction and amelioration of monocyte inﬁltration in
the kidney after ureteral obstruction, which provides evidence
that sulfatide is an endogenous ligand of L-selectin.
478,479 Studies
of sulfatide deﬁciency have also utilized mice that are genetically
deﬁcient in UDP-galactose: ceramide galactosyltransferase be-
causetheinabilitytosynthesizegalactosylceramideprecludesthe
biosynthesis of sulfatide bysulfation of GalCer
480 and have com-
pared the morphological features between the galactolipid-null
and the sulfatide-null mice.
481 Reduced formation of sulfatides
has been suggested to play a role in polycystic kidney disease.
482
3.2.4.IntegrationofBackboneandHeadgroupBiosyn-
thetic Pathways. Figure 9 provides a symbolic representation
of sphingolipid biosynthesis de novo from the perspective of
both the lipid backbones and the headgroups.
3 Panel A explains
the layout for the sphingolipids made from Ser, with the first
node representing 3-ketosphinganine; the next, sphinganine;
then fanning out to form a ring that represents the ensemble
ofN-acyl-sphinganines(withthefattyacidchainlabeledinblue);
from which the different categories of headgroups are added, as
indicated in the blow-out in the upper portion of panel A. Thus,
eachfanblade representsallofthe headgroupderivatives forone
N-acyl-sphingoid base backbone. Panel B illustrates how this
schemeexpandsasoneincludesallthreetypesofsphingoidbases
made by SPT using Ser (for sphinganine, d18:0), Ala (for
1-deoxysphinganine, m18:0) and Gly (for 1-desoxymethylsphin-
ganine, m17:0). The initial from each of these represent the
N-acyl-derivatives followed by headgroup addition, as shown in
panelA(notethatthebladesofthefansform18:0andm17:0do
notextendbeyondthefirstringbecauseneitheroftheseundergo
headgroupaddition),andthelinesthatconnecttheinnerringsto
the next fans represent the desaturation of the sphingoid base
backboneseachoftheseN-acyl-sphingoid bases(e.g., converting
DHCer, N-acyl-d18:0, to Cer with an N-acyl-d18:1 backbone,
etc.). Also shown are the additional backbones from 4-hydro-
xylation of DHCer by DES2 to form the t18:0 backbone, and
desaturation of Cer to produce the sphingadiene backbone
(d18:2) (and others could be added for additional modifications
to the sphingoid base chain). The 1-deoxy- and 1-desoxymethyl-
sphingoid bases might also undergo these further backbone
modifications, but we have not yet seen these products by mass
spectrometric analysis of mammalian samples (unpublished
observation), so they have not been added to the scheme. For
a representation of all of the sphingolipids that can be made de
novo, one would display several of these maps, with one for each
fatty acyl-CoA that is utilized in the first step (for examples,
myristoyl-CoA for the d16:0 sphingoid base chain length;
stearoyl-CoA for d20:0, etc.). This type of diagram is mainly
useful as a mental exercise to appreciate the pathways that would
produceeveryindividualmolecularsubspecies;however,itmight
be possible someday topopulateitwithcolored pixels represent-
ing the relative amount of each subspecies (or differences in
amountsbetweentwosources,asinageneexpressionheatmap),
to facilitate visualization of patterns or interrelationships that
would otherwise be difficult to appreciate.6405 dx.doi.org/10.1021/cr2002917 |Chem. Rev. 2011, 111, 6387–6422
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The elements of this scheme occur in discrete (and often
multiple) locations in the cell, where particular combinations of
theenzymes,cosubstrates,traﬃckingproteins,etc.,makeamajor
contribute to the outcome. Further discussion of this facet of the
biosynthetic pathway is beyond the scope of this review, except
for the few instances that have been presented with a particular
metabolic step, such as the compartmentation of GalCer bio-
synthesis in the lumen of the ER.
3.3. Sphingolipid Turnover, Trafficking, and Recycling
Metabolichomeostasisforthesphingolipidomeisachievedby
balancingbiosynthesis,degradation,recycling,andprocessesthat
add exogenous sphingolipids to, and remove them from, the cell.
This review is concerned mainly with sphingolipid biosynthesis
but will also brieﬂy address these other processes because they
are interrelated and should be kept in mind. Metabolic turnover
is deﬁned as any process that hydrolyzes a complex sphingolipid
to component parts. This usually occurs via lysosomal enzymes
483
and, if the intermediates are not recycled, is followed by the
irreversible degradation of the sphingoid base to products that
are no longer categorized as sphingolipids (e.g., a fatty aldehyde
andethanolaminephosphate)inthecytosol.
484Hydrolyticenzymes
for sphingolipids are also found in other locations in the cell to
producebioactiveproductsforcellsignaling
5,6andrearrangementof
membrane architecture.
23,485 The complete balance sheet for
sphingolipids additionally includes uptake of sphingolipids from
exogenous sources (such as albumin and lipoproteins)
486,487
and losses by eﬄux,
488 lipoproteinsecretion,
354,489 and shedding
of membrane vesicles containing sphingolipids.
490
3.3.1. Metabolic Turnover. The major steps in the hydro-
lysis of complex sphingolipids are summarized in Figure 10,
which has the same basic pathway layout as for the other figures
for self-consistency. Most of these steps were discovered in the
course of understanding genetic diseases that had been noted to
involve accumulation of a particular category of sphingolipid.
483
As the lysosomal hydrolases were characterized and in some
Figure 9. Backbone and headgroup relational depiction of mammalian sphingolipid biosynthesis. This alternative depiction of de novo sphingolipid
biosynthesis displays how the pathway can be envisioned to start with a fatty acyl-CoA (palmitoyl-CoA in lower portion of panel A) that is condensed
withSertoform3-ketosphinganinethensphinganine(atthecenterofthefan),whichisN-acylatedtoproducediﬀerentchain-lengthdihydroceramides
(represented by the ring, with examples of chain lengths labeled in blue). Each dihydroceramide subspecies can be converted into families of dihydro-
complex sphingolipids, which are symbolized by the blades. The upper portion of panel A shows some of the complex sphingolipids within each wedge
(whichareonlyafractionoftheactualnumberofcompoundsthatcanbemade,asillustratedbyFigures7and8,andthediscussioninthetext).PanelB
displaysfurthercomplexitiesrelatedtothelipidbackbones.TheupperportionofpanelBillustrateshowthedihydroceramidesfromeachsphingoidbase
backbone (in this case, d18:0 from palmitoyl-CoA) can be hydroxylated to phytoceramides (t18:0) and/or desaturated to ceramides (d18:1) (c.f.,
Figure4);thelatterisalsopresumedtoundergofurtherdesaturationtoformN-acyl-sphingadienes(d18:2).ThebladesradiatingfromeachN-acyl-chain
subspecies represents the complex sphingolipids, as explained for panel A. The lower portion of panel B shows that Ala or Gly are alternatively used by
serine palmitoyltransferase to form m18:0 and m17:0 which are N-acylated and, to some degree, desaturated to N-acyl-m18:1’s and N-acyl-m17:1 (to
date,backbonehydroxylationhasnotbeennoted).Notethatthesedonotradiateintolargerbladesbecauseheadgroupscannotbeadded.Notshownare
theutilizationofotherfattyacyl-CoAs,whichwouldconstituteparallelschemeslikethese,norpathwayswheresphingolipidsareturnedovertogenerate
intermediates that are recycled or turned over(although one can envision thisoccurring within the blades to returnto the hub, withthe apex ofthe hub
representing the free sphingoid base). The symbols and abbreviations are the same as have been used in the other ﬁgures in this Review.6406 dx.doi.org/10.1021/cr2002917 |Chem. Rev. 2011, 111, 6387–6422
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cases found not to be mutated despite the appearance of disease
symptoms in some of the patients, accessory proteins (such as
GM2activatorproteinshowninFigure10)werefoundalsotobe
important. In addition to these, one disease that appeared to be
due to defective sphingolipid turnover, Niemann Pick type C
disease (due to accumulation of sphingomyelin, although that
was erratic), was found not to be due to a genetic defect in an
enzyme of sphingomyelin metabolism but rather a lipid trans-
porter that affects multiple categories of lipids.
491 If the reader is
interested in more information about the diseases resulting from
defects in sphingolipid metabolism, at least three outstanding
reviews of that topic have been published recently.
295,483,492
Over time, some sphingolipids were found to be hydrolyzed
not only by lysosomal enzymes (with acidic pH optima) but also
by enzymes with neutral or alkaline pH optima. These include
sialidases in the plasma membrane (which are able to modulate
cell regulation by gangliosides)
493 and nuclear membranes
(the latter apparently to produce GM1 by hydrolysis of GD1a
for nuclear function),
494 plasma membrane β-galactosidase and
β-glucosidase (which is active without activator proteins and
displays a trans activity in living cells),
495 alkaline,
496 and
neutral
497,498 sphingomyelinases as well as multiple ceramidases
(at least ﬁve humanceramidases encodedby distinct genes: acid,
neutral, and three alkaline ceramidase)
499 that have functions
fromsphingolipiddigestiontocellsignaling.Therefore,turnover
of sphingolipids occurs in a large number of locations: in the
extracellularenvironment(e.g.,asinsphingolipiddigestioninthe
lumen of the intestine), on the extracellular and intracellular
surfaces of the plasma membrane, and associated with multiple
intracellular organelles.
3.3.2.SphingolipidTraffickingandMembraneDynamics.
The general scheme for sphingolipid biosynthesis and trafficking
thathasbeeninplaceforsometime
500,501isthatCerisproduced
de novo in the ER
253 then transported to the cis-Golgi via
vesicular trafficking or the trans-Golgi by CERT,
410 where more
complex (glyco)sphingolipids are made (with the differential
localization of CERK, SM synthases and specific glycosyl-
transferases influencing the partitioning of the intermediates
into the endproducts)
463 and (mostly) delivered to the plasma
membrane to enrich it with sphingolipids and cholesterol.
501
ThistraditionalpathwayisschematicallyrepresentedinFigure11
by black arrows. Other routes of sphingolipid relocation in cells
include transbilayer movement by ATP-binding cassette (ABC)
family of membrane-bound transporters,
502 which may also be a
pathway for efflux of S1P,
503 intermembrane transfer via the
Glycolipid Transfer Protein (GLTP) superfamily
504 and other
transporters such as MDR2 (P-glycoprotein) and the cystic
fibrosis transmembrane regulator (CFTR).
505
Inward traﬃcking of sphingolipids is illustrated by the green
arrows in Figure 11. This was initially deﬁned as “housekeeping”
turnover of sphingolipids via internalization of membrane vesicles
that are sorted into components for lysosomal hydrolysis, with
the released sphingosine being degraded or recycled as summar-
ized,respectively,insections3.3.1and3.3.3.Cellularmembranes
additionally enter the lysosomal compartment by autophagy
during phagocytosis,
506 which is thought to use autophagy
Figure 10. Sphingolipid turnover and catabolism. Representative enzymes and intermediates are shown for the turnover of each complex sphingolipid
family to the lipid moiety (Cer), and the insert displays the degradation of the sphingoid base by phosphorylation and lytic cleavage to a fatty aldehyde
and ethanolamine phosphate. The symbols and abbreviations are the same as have been used in the other ﬁgures in this Review.6407 dx.doi.org/10.1021/cr2002917 |Chem. Rev. 2011, 111, 6387–6422
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componentstofacilitateacquisitionoflysosomalenzymesbythe
phagosome.
507 509 Since sphingolipids are components of au-
tophagosomes (and are required for induction of autophagy),
510
they are likely to be hydrolyzed when the autophagosome
becomes acidic and acquires lysosomal hydrolases. Retrograde
traﬃcking from the plasma membrane to the Golgi and ER
provides another pathway for inward movement of sphingoli-
pids, and has been studied mostly from the perspective of how it
provides a mechanism for bacterial toxins that bind glycosphin-
golipids (e.g., GM1 for cholera toxin;
511 Gb3 for Shiga toxin
512
and verotoxin
513,514) to gain access to the ER.
In addition to these processes, there are many interesting and
not-yet-fully explained observations that reveal that the metabo-
lism and traﬃcking of sphingolipids is even more complicated.
Forexamples,ithasbeennoted:thatatleastonesubunitofserine
palmitoyltransferase appears in the nucleus and focal adhesions
and aﬀects cell morphology;
251 that ceramide synthesis
(N-acylation) occurs not only in the ER but to some extent also
in mitochondria,
339,360 a site where Cer production or targeting
can induce cell death;
515,516 that GlcCer destined for glycolipid
synthesis appears to be made in the Golgi but is transported
back into the ER (via FAPP2) before achieving access to the
lumen of the Golgi,
435apparently becausethe FAPP proteinsare
involved in forming a tubular network that eﬀects transport;
437
that cells make GalCer in the lumen of the ER,
468,517 raising the
possibility that slowed traﬃcking of Cer from the ER to Golgi
(and,thus,moretimeforCertoﬂipfromthecytosolictoluminal
leaﬂet) might contribute to the elevated biosynthesis of Gala
series glycosphingolipids in stressed cells
518 and that enzymes of
sphingolipid metabolism are being found in many other regions
of the cell, including the nucleus
207 and the outer leaﬂet of the
plasma membrane, where there are “ecto” glycohydrolases
519
and glycosyltransferases,
520 including a recently described ecto-
sialyltransferase (ecto-Sial-T2) that is able to sialylate GM3
exposed on the membrane of neighboring cells using CMP-N-
acetylneuraminic acid in the extracellular milieu.
521
Other exported (secreted) enzymes include sphingosine
kinase,
522,523 neutral,
524,525 and acidic
525 ceramidase, and acid
sphingomyelinase.
31 Acid sphingomyelinase is a particularly
interesting case because it appears to have multiple func-
tions,
526,527 including to be secreted by cells upon membrane
wounding to facilitate endocytosis of the aﬀected region of the
membrane, perhaps by inducing membrane curvature.
528 This
introduces the third category of traﬃcking processes, repre-
sented by the red arrows in Figure 11, which include vesicle
fusion and traﬃcking,
529 formation of autophagosomes (discussed
above) and multivesicular bodies (which have been proposed to
provide a mechanism to release autophagosomes via “unconven-
tional” vesicular secretion),
530 release of membrane particles
(microvesicles, shed vesicles, exosomes and ectosomes), as well
astheendocytoticprocessesdiscussedabove.Manyofthesehave
already been found to involve sphingolipids, such as that Cer
modulates the rate of ER to Golgi traﬃcking,
531 induces
autophagy
532(asalsodoesdihydroceramides),
97generatesdynamic
Figure 11. Schematic representation of the locations in and outside of the cell where sphingolipids are metabolized and traﬃcked. The black dashed
linesshowthetraditionalbiosyntheticpathwaybeginningwithbiosynthesisofthelipidbackboneintheERandsubsequenttraﬃckingthroughtheGolgi
for further metabolism, leading ultimately to movement to the plasma membrane and other parts of the cell via vesicles and transport proteins
(e.g.,GLTP)oracrossthemembraneviapumps(ABC,etc.).Thegreenarrowsreﬂectinwardmovementofsphingolipidsdestinedtolysosomesortothe
ER via retrograde motion. The red lines represent additional traﬃcking of sphingolipids; for examples, for autophagosome formation, formation of
multivesicular endosomes and multivesicular bodies, and fusion with the plasma membrane as shown.6408 dx.doi.org/10.1021/cr2002917 |Chem. Rev. 2011, 111, 6387–6422
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membraneasymmetryforpromotionofmembranecurvature,
533
and triggers budding of exosome vesicles into multivesicular
endosomes.
534 Some of these processes might reﬂect a speciﬁc
sorting process, as has been proposed to occur in a subapical
compartment or common endosome,
535 or might be a manifes-
tation of the biophysical properties of Cer, or perhaps an
indicator of the broader process such as raft formation,
536,537
with Cer serving as just one of many participants. In any event,
these rapidly evolving subjects are very likely to change the way
that we think about sphingolipid homeostasis.
3.3.3. Sphingolipid Recycling (Salvage Pathways). This
review has referred only briefly to the reutilization of sphingo-
lipids after they have beenturned over to the free sphingoid base
or other intermediates, which has been discussed in at least two
excellent reviews.
538,539 This is clearly an aspect that requires
attention not only with respect to the contribution of salvage
pathwaystooverallhomeostasisbutalsofor itsimplicationsfor cell
signaling studies where exogenous sphingolipids have been added
to cells in culture. Studies of the recycling of endogenous sphingo-
lipids is extremely difficult because the precursors that would be
used for the labeling (palmitic acid, serine, etc.) are themselves
interconnected with numerous other metabolic pathways.
Studies of the fate of exogenously added sphingolipids have
found that they are reutilized, but in complicated ways. Complex
sphingolipids labeled in the sphingosine backbone are taken up
bycellsincultureandhydrolyzedandreutilized,butasubstantial
amountisrereleasedintotheculturemedium,whichimpliesthat
they receive special handling.
487 This loss to the medium is very
intriguing and is consistent with the ﬁnding that microvesicles
releasedfromcells inculture are enriched insphingolipids,
540,541
and more recently that ceramide triggers budding of exosome
vesicles into multivesicular endosomes.
534
Exogenously added short chain (C6-) ceramides are exten-
sively hydrolyzed and reacylated with long-chain fatty acids,
542
and studies with A549 human lung adenocarcinoma cells found
that the generation of endogenous long-chain ceramide in
response to exogenous C6-Cer was regulated by reactive oxygen
species.
543AcomparisonofC2-andC6-ceramidesfoundthatthe
former was not hydrolyzed and recycled like the latter, and
proposed that this accounts for diﬀerences in the ability of these
chain length subspeciestoinduceapoptosis (i.e., C6-Cer ismore
potent in inducing apoptosis).
544 Other types of exogenous
ceramides, such as ﬂuorescent derivatives with the fatty acyl
position occupied by a 6-[N-(7-nitro-2,1,3-benzoxadiazol-4-
yl)amino]hexanoyl-group(i.e.,C6-NBD-),arealsoreadilytaken
up and converted to more complex sphingolipids
545 (with
interesting diﬀerences between diﬀerent stereoisomers and
NBD-dihydroceramides and NBD-ceramides).
371 Exogenously
added sphingoid bases are rapidly taken up, phosphorylated,
546
acylated
277 and converted to more complex metabolites
92 de-
pending on the structure of the sphingoid base. The story is also
complicated (and perhaps even more so) for sphingosine
1-phosphate, which has been shown to be hydrolyzed by the
extracellular lipid phosphatase LPP-1, which facilitated uptake of
the sphingosine, followed by its intracellular rephosphorylation
by sphingosine kinase (SphK1).
547 The Spiegel lab has shown
that a similar phosphorylation-dephosphorylation cycle is in-
volved in reutilization of sphingosine in mammalian cells and
appears to take place in the endoplasmic reticulum via sphingo-
sine-1-phosphate phosphohydrolase 1 (SPP-1) and sphingosine
kinase 2 (SphK2).
548 SPP1 is an endoplasmic reticulum-resident
enzyme that speciﬁcally dephosphorylates S1P, and its depletion
has also been shown to induce ER-stress and autophagy,
processes that alter ER/Golgi traﬃcking.
549
Takeninconcert,onewondersifitistechnicallyfeasible toadd
exogenous sphingolipids to cells and accurately deduce how
endogenous sphingolipids behave because they not only follow
diﬀerent membrane traﬃcking pathways but also possess biologi-
cal activities that perturb cell behavior. Similar concerns apply to
studies using overexpression or knockout of genes for enzymes of
the pathway. This is unsettlingly analogous to the Heisenberg
uncertaintyprincipleforquantummechanics,therefore,onemight
consider referring to it as the “sphingolipid uncertainty principle”.
4. ANALYSIS OF SPHINGOLIPID METABOLISM BY
“OMIC” TECHNOLOGIES
The sphingolipidome is theoretically deﬁned as all of the
molecular subspecies of sphingolipids in an organism or other
system of interest, and as the discussion above has illustrated, this
encompassesalargenumber ofindividualmolecularspecieswhen
both headgroup and backbone variation are taken into account.
Manytypesofmethodsareavailableforstudyingsphingolipids;
550
however,sphingolipidomicanalysesareusuallyconductedbymass
spectrometry because both the sphingolipid category and molec-
ularsubspeciescan be determined.But, asis thecase for the other
omics, current methods actually encompass only a fraction of the
members of this family of compounds, therefore, a sphingolipi-
domic analysis describes compounds within a particular frame of
reference (for example, all of the early metabolites of de novo
sphingolipid biosynthesis, such as the ones shown in Figure 4).
This can, nonetheless, provide very useful information about
sphingolipid metabolism, especially when stable isotope-labeled
precursors are used to track the newly made metabolites.
551
4.1. Use of Mass Spectrometry for Sphingolipidomics
Mass spectrometry is not a “one size ﬁts all” technology
because diﬀerent categories of compounds form ions more or
lessreadily(andsomearediﬃculttoionizewithoutsomedegree
of decomposition in the ion source, such as loss of sialic acid or
dehydration), there are numerous instances where isomeric and
isobaric compounds complicate the analysis and require the
additional steps (chromatographic separation of GlcCer and
GalCer, for example), and other components in the sample can
interfere with the analysis by ionization suppression, clogging of
columns and electrospray needles, and many other technical
glitches.Theseconsiderationshavebeenrecentlydiscussedfrom
many perspectives.
34,552 555 In general the major challenges in
MS analysis of sphingolipids are (a) to obtain standards both for
methods development and to serve as internal standards (at
present, these are only available for a small fraction of the known
sphingolipidsubcategories);(b)toidentifyextractionconditions
where the analytes of interest and selected internal standards are
recoveredinhighyieldwhetherhighlypolar(gangliosidesandS1P),
nonpolar (ceramides), vary in chain length and other biophysical
features; (c) to develop complementary methods (usually
chromatographic)toseparatecompoundsthatarenotdistinguished
by MS alone, which includes the usually thought of isomers and
isobarsaswellasoccasionswhererelativelyminorisotopomers(e.g.,
withseveralnaturalabundance
13C) ofamajorspeciesoverlapswith
the m/z of a compound that is present in the biological sample in
much lower abundance; (d) to optimize the ionization, fragmenta-
tion and detection parameters to gain maximal information from
each compound, and to simply comparison of unknowns with the6409 dx.doi.org/10.1021/cr2002917 |Chem. Rev. 2011, 111, 6387–6422
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matched internal standards; (e) to have relatively rapid and facile
ways to collect and analyze large data sets; and (f) to be able to
display thedata in waysthatenablelargeamountsof information to
be understood as easily and fully as possible.
Ideally,internalstandardsshouldhavethesamestructureasthe
analyte and vary only in m/z—usually as a stable isotopically
labeledversion;however,thisisnotpracticalforlipidomicanalysis
and suitably selected representatives of subcategories of com-
poundsareused.Aninternalstandardcocktailhasbeendeveloped
by the LIPID MAPS Consortium and is commercially available
from Avanti Polar Lipids (Alabaster, AL). It contains uncommon
chain-length sphingoid bases (C17) for sphingosine, sphinganine
and their 1-phosphates (S1P and Sa1P) and d18:1;C12:0-fatty
acidCer,Cer1P,SM,andmono-anddihexosylCer,andthiscanbe
supplemented with additional internal standards, as desired.
In our experience, it is diﬃcult to extract both the nonpolar
(e.g.,Cer,SM,andhexosylCer)andthemorepolarsphingolipids
(sphingoid base phosphates, Cer1P, etc.) using one solvent
protocol; therefore, we divide the sample into two fractions:
one that is later split into separate organic and aqueous phases
(for the less polar sphingolipids) and one that is never divided
intotwophases(fortherelativelywater-solublesphingolipids).
39
This protocol was subsequently altered to substitute methylene
chloride for chloroform in all steps with free sphinogid bases to
avoid the possibility of modiﬁcation of the free amine via
formation of carbene in basic conditions. The published extrac-
tion protocol gave high recoveries of all subspecies (i.e., SM,
hexosylCer and Cer with C12- to C26-fatty acids); however, we
have noted that when samples have a large amount of lipid (as is
often encountered with plasma, liver and brain), extra eﬀort may
be required to redissolve all of the sphingolipids in the ﬁnal
extract in the LC solvent for LC-ESI-MS/MS, resulting in
disproportionate losses of the very-long-chain subspecies.
Liquid chromatography
39,552,556 is useful not only for the
separation of isomeric and isobaric species (such as GlcCer from
GalCer), but also tends to reduce ionization suppression. Re-
versed phase LC
39,557 559 is used for separations based on the
length and saturation of acyl chains (for example, to separate
So and Sa), and normal phase LC
39,220,557,560 562 to separate
compounds primarily by their headgroup constituents (for
example, distinguish Cer, GlcCer, LacCer, globotriaosylcera-
mide, globotetraosylceramide, SM as well as cholesterol, etc.).
LC-ESI MS/MS is the most popular analytical tool for sphingo-
lipidanalysis(asrepresentedbytheapplicationscitedabove,and
more),
563 567 because sensitivities are on the order of fmol (or
less), which allows analysis of small biological samples (such as
∼10
5 10
6cellsinculture)whileprovidingawidedynamicrange
(typically several orders of magnitude), which allows analysis of
both trace metabolites, such as the sphingoid base 1-phosphates
and major structural species (SM). Results from a LC-ESI MS/
MS method that has been developed following these principles
(and the internal standard cocktail available from Avanti Polar
Lipids, Alabaster, AL)
39 can be seen in a recent study of the
sphingolipidsinRAW264.7cellsactivatedbyKDO2 LipidA.
510
It warrants comment that thin-layer chromatography has also
beencombinedwithMALDI-MS/MSforanalysisofsomeofthe
diﬃcult to distinguish glycosphingolipids.
568 570
Although quantitative analyses have most often used electro-
spray to ionize sphingolipids,
39,550 other ionization methods
have included atmospheric pressure chemical ionization, APCI,
562
desorptionelectrosprayionization(DESI),
571aswellasMALDI,
572
which is not always thought of as a quantitative method, but can
be with the appropriate controls. MALDI has particularly aided
the analysis of more complex glycosphingolipids,
573 575 but
might also be applied to smaller molecules (which typically have
been obscured by background chemical noise from the MALDI
matrix ions) new advances in matrix choices and high-pressure
sources.
572,576 580
Ionseparationandmassanalysisismostfrequentlyconducted
using triple quadrupole or tandem quadrupole-linear ion trap
mass analyzers for MS/MS and MS
n,
39,133,552,581 respectively, or
for higher mass accuracy, time-of-ﬂight (TOF),
582 orbitrap
583 or
Fourier transform (FT) instruments;
584 586 ion mobility MS
hasalsobeenrecentlyappliedtosphingolipids.
587Fragmenta-
tion in MS/MS mode is achieved by a number of ways,
depending on the type of compounds involved, and include
collision induced dissociation (CID) with nitrogen for most
applications and, in a novel approach to determine double
bond position, ozone;
588 a recent use of the ion trap to favor
backbone fragmentation of SM;
39 and electron transfer dissociation
(ETD) for analysis of glycans.
589 Analysis of higher glycosphingo-
lipids can also be conducted by removal of the lipid moiety using
endoglycoceramidase,
590 followed by analysis of the glycans by
mass spectrometric methods used to characterize O- and
N-linked glycans from glycoproteins.
591
Althoughsphingolipidsarecomplex,manyarerelativelyeasily
ionized and can be fragmented to ions that allow the sphingoid
base and amide-linked fatty acid to be determined; therefore,
stable-isotopelabeledprecursors(suchasU 
13C-palmitate)can
be used to follow biosynthesis of the sphingoid base backbone as
well as N-acylation.
551 In this example,
13C appears in three
isotopomers and isotopologues: [M + 16 for the sphingoid base
or N-acyl fatty acid, and [M + 32] for both), in addition to the
unlabeled species (corrected for the natural abundance
13C
species). In interpreting the data, one needs also to determine
the isotopic enrichment of palmitoyl-CoA (i.e., the fraction with
13C- versus endogenous
12C-palmitoyl-CoA) and ideally also
that for longer chain fatty acyl-CoA’s that are made by desatura-
tion and/or elongation reactions before incorporation into
N-acyl-sphingolipids, which is technically feasible by a recently
developed method for LC-ESI-MS/MS analysis of fatty acyl-
CoAs.
288 This study used 0.1 mM [U 
13C]palmitate (added as
the 1:1 complex with bovine-serum albumin) to try to remain
within the concentration usually found in circulation,
592 in an
attempttocauseminimalperturbationofthetotalcellularpalmitoyl-
CoA because this compound has been shown to aﬀect gene
expression,
593,594 ion transport,
595 and sphingolipid biosyn-
thesis.
294,296 Nonetheless, even this low amount, which achieved
about 50% labeling of the total cellular palmitoyl-CoA, elevated
the amount in the cells by about 3-fold. An alternative approach
might be to use [
13C]acetate to label the endogenous palmitoyl-
CoA pool, but quantitative analysis of the labeling is more
complicated,
596 598 or to use labeled serine, which has the
disadvantage that it only shifts the m/z of the labeled sphingo-
lipids by a few amu (not to mention that serine also participates
in multiple metabolic pathways). For some applications, it is also
useful to add an exogenous sphingolipid that can be tracked
becauseithasanunusualstructure,suchasanoddchainlengthor
ﬂuorescence tag.
539
4.2. Tissue-Imaging Mass Spectrometry of Sphingolipids
Studiesof sphingolipidmetabolisminvivo arecomplicatedby
the loss of information about histological localization of the
compounds of interest after the tissues have been homogenized6410 dx.doi.org/10.1021/cr2002917 |Chem. Rev. 2011, 111, 6387–6422
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for extraction and analysis. This can be addressed, in some cases,
by a more direct method of analysis that is broadly called
“imaging mass spectrometry,”
599 and the speciﬁc application
described below has been termed “MALDI imaging mass
spectrometry.”
600 In this procedure (in general, and as
applied to sphingolipids),
601 a tissue (and sometimes an entire
animal)
602 is usually frozen and sliced (the thickness varies, but
is usually on the order of ∼10 μm), and adjacent sections are
often placed on a chilled MALDI plate and a glass slide, so the
MALDI image can be compared to the histologic appearance of
the tissue using traditional staining. MALDI matrix compound is
imbedded in the sample as uniformly and nondisruptively as
possible, then a laser beam is moved incrementally across the
sample to generate ions and collect MS and sometimes MS/MS
spectra for regions ∼50 μm in diameter (larger, and sometimes
smaller, regions can be chosen for each spectrum; however, the
technique is usually limited to a histological, that is, one or a few
cells,ratherthanasubcellularscale;subcellularanalysisrequiresa
diﬀerent method for generating ions that is under develop-
ment).
603 MALDI-imaging MS produces thousands of spectra
for samples even only 1 mm
2 which are analyzed using imaging
software to locate speciﬁc m/z of interest (representing com-
pounds chosen by the user, or other criteria such as abundance,
coclustering, and other features), and these are plotted in x,y-
space to yield a virtual molecular image of the distribution of the
ions, with color coding that reﬂects diﬀerent compounds, or
displays the relative abundance of a speciﬁc ion (in a heat map
style). These images can be cross-referenced with adjacent slices
to orient where the ions of interest are located with respect to
more traditional histological markers.
An approach to enhance the sensitivity of imaging MS has been
to use gold nanoparticles in place of the usual MALDI matrix
compounds (in a technique called nanoparticle-assisted laser
desorption/ionization MS, or nano-PALDI-imaging mass spectro-
metry).
604,605 F o rm u c hh i g h e rr e s o l u t i o n( < 1μm), secondary ion
massspectrometry(SIMS) hasbeenused,
606butthehighenergyof
the ion beams causes extensive fragmentation of lipids. This has
been circumvented by using a focused buckminsterfullerene (C60)
cluster ion beam that is less destructive to the lipids.
603
Thistechniqueishighlyinformativewhenappliedtolipids.
607,608
Someoftheﬁndingsforsphingolipids fromapplicationoftissue-
imaging mass spectrometry have been: to localize the areas of
accumulation of di- and trihexosylceramides in cutaneous biopsies
from patients with Fabry’s disease (a study that used both MALDI
and SIMS);
609 to proﬁle the normal distribution of lipids within
humanskin;
610tocharacterizethelipidcompositionofatheroma;
611
to describe the sphingolipids of the human lens with aging;
612 to
discover and localize elevated sulfatides in ovarian cancer;
180 to
examine the lipids of lung,
613 and lungs infected with C. neoformans
and ﬁnd that speciﬁc SM species are associated with neutrophil
inﬁltration at the site of the infection;
614 a n dt os t u d yi ns o m e
depth the distribution of sphingolipids in brain using MALDI
and SIMS imaging MS,
571,575,606,607,615 618 with the interesting
ﬁndings including the distinct localization of gangliosides with
thed20:1-sphingoidbasebackbone,
53andaccumulationofGM2
and GA2 in a mouse model for Tay Sachs/Sandhoﬀ disease.
619
Astheseexamplesshow, imagingMShasalready proventobe
useful in identifying speciﬁc molecular subspecies and histological
locations of sphingolipids under a wide range of normal and
abnormal physiologic conditions; therefore, it is reasonable to
think that it will become increasingly valuable as a tool for
metabolic studies as the technology becomes better reﬁned and
there are more research centers with the instruments (and
knowledgeable operators). Although they have thus far had only
limiteduse,stableisotope-labeledsphingolipidscanbediscerned
by this form of mass spectrometry, too, so imaging studies can
add a dynamic component. There are still limitations with
respect to its ability to resolve isomeric and isobaric compounds
and to provide absolute quantitation, however, these can be
addressed to some extent by using both standard and imaging
mass spectrometry as part of the investigation.
5. INTEGRATION OF “OMIC” DATA SETS FOR A SYS-
TEMS BIOLOGY OF SPHINGOLIPID METABOLISM AND
FUNCTION
Atypicalanalysis of the major sphingolipids of cells in culture,
plasma and other sources using lipidomic methods generally
produceshundredstothousandsofdatapoints,andthenumberwill
expand by several orders of magnitude when methods are available
tolookatallofthesubspecies,whichputsthesphingolipidomeon
thescaleofotheromicdatasets.Therefore,sphingolipidresearch-
ersfacethechallengeofall“omics”disciplines,toﬁgureouthowto
handle and visualize such large amounts of data, mine large data
sets for relationships that have not been previously seen by more
focused approaches, and integrate what has been (and will
continue to be) learned by traditional reductionist approaches
with the data produced by metabolomic, transcriptomic, and
other omic analyses. There are several ways to envision
accomplishing these goals, such as to develop relatively facile
ways to visualize the information and, ultimately, to develop
mathematical models for all of the components of the system.
5.1. Visualization Tools
Graphic display is often the most eﬀective way to commu-
nicate data, if done cautiously.
620,621 This is particularly true for
large data sets and complex pathways because, as has been well
stated by Alan Aderem, Director of the Institute for Systems
Biology: “Human minds are incapable of inferring the emergent
propertiesofasystemfromthousandsofdatapoints,butwehave
evolved to intelligently interpret an enormous amount of visual
information” (http://www.systemsbiology.org/technology/data_
visualization_and_analysis).
A typical analysis of the major sphingolipids of cells in culture
using lipidomic methods will generally produce hundreds to
thousands of data points, which puts it on the scale of transcrip-
tomic data sets, where use of heat maps and other types of
visualization tools have become commonplace. In heat map
format, lipidomic data are often displayed in the order of
N-acyl-chain length or summed carbon number, mass (or m/z,
if the data are from mass spectrometry), and sometimes divided
into lipid subcategories
622 and/or hierarchial clustering.
623
Several additional visualization schemes have been developed
for mammalian sphingolipid metabolism
3 to display all of the
molecular subspecies in a pathway format, similar to Figure 4 (as
illustrated in Figure 1 from a recent analysis of de novo
sphingolipid biosynthesis by activated RAW264.7 cells),
624 or
using a platform of pathway tools prepared by LIPID MAPS
(http://www.lipidmaps.org/pathways/index.html) that can also
showtimecoursedata.Otherdisplayformatshavebeenprepared
for the glycosphingolipids by the Consortium for Functional
Glycomics (www.functionalglycomics.org). One report de-
scribes a way to extend the visualization of complex sphingolipid
pathways via an interactive visualization tool.
6256411 dx.doi.org/10.1021/cr2002917 |Chem. Rev. 2011, 111, 6387–6422
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Anapproachthatwehavefoundtobeuseful
290allowsvisualization
of both transcriptomic and metabolomic data sets using an open
access pathway browser, Pathvisio v1.1,
626 and KEGG-style pathway
maps (Kyoto Encyclopaedia of Genes and Genomes) that have been
updated and expanded for sphingolipid metabolism.
290,554 In illustrat-
ing the use of this tool, microarray data for two breast cancer cell lines
(MDA-MB-231 versus MCF7 cells) were compared and based on
diﬀerencesintheapparentdiﬀerencesinmRNAabundances,possible
diﬀerences in sphingolipid subspecies were made and evaluated by
analysis of the sphingolipid compositions of the cells by mass
spectrometry.
290 Two of the predicted diﬀerences that were thus
conﬁrmed were in the nature of the sphingoid bases in the cells, both
with respect to chain length (i.e., higher proportions of C16-sphingo-
sine in the cells with the relatively higher expression of SPT3) and
4-hydroxylation (i.e., higher proportions of 4-hydroxysphinganine,
phytosphingosine, in the cells with the relatively higher expression of
DES2). When data from a wide range of cancer cell lines, tumors and
normal tissues were considered, there was a surprisingly high prob-
ability of match between the gene expression data and sphingolipid
composition (73%),
290 considering that there are multiple mechan-
isms for regulation of metabolism beyond transcript amount.
Asimilarapproachhasbeenusedtocomparegeneexpressiondata
from mouse embryoid bodies versus embryonic stem cells, deter-
mined by quantitative real-time PCR (qRT-PCR) with the sphingo-
lipid composition determined by massspectrometry.
336And, to take
this approach a further step, it was also used to interpret a gene
expression data set for ovarian cancer cells obtained by laser capture
microdissection (versus normal human ovarian epithelial cells),
which led to the prediction that sulfatides are elevated in human
ovarian cancer, which was ﬁrst conﬁrmed by LC-ESI-MS/MS and
then the sulfatides were speciﬁcally localized to ovarian epithelial
carcinoma cells versus the neighboring stromal cells by tissue-
imaging MS.
180 This simple integration of two types of “omic”
technologies(“transcriptomics”todirect“sphingolipidomics”)could
facilitatethediscoveryofnewfacetsofhowsphingolipidmetabolism
is regulated, relationships between sphingolipid metabolism and
disease, and possibly the identiﬁcation of new biomarkers.
5.2. Mathematical Modeling
Mathematical modeling of metabolic pathways and functions is a
rapidly developing science,
627 but is diﬃcult to apply to the sphingo-
lipidome because the pathways are not only complex but still have
many yet-to-be-discovered elements. The most comprehensive at-
tempts toward this objective, to date, have been made with yeast
Saccharomyces cerevisiae because its sphingolipid biosynthetic pathway
has fewer genes and metabolites.
628 630 The models appear to be
compatible with the available information about gene expression
levels, the kinetic properties of the enzymes, metabolite amounts,
etc.
628 630andhowperturbations,suchasdrugs,
631heatstress,carbon
source utilization, sporulation, cell wall integrity, and others aﬀect this
system.
632Acombinedintegrativeanalysisofgenomic,transcriptomic
and lipidomic data revealed a signaling role for phytosphingosine-1-
phosphate in regulating genes required for mitochondrial respira-
tion.
633 Mathematical modeling has also been applied to Cryptococcus
neoformanstoexploresphingolipidmetabolismintheorganismunder
acidic conditions with the goal of better understanding fungal
pathogenesis.
634Theapplicabilityofthisapproachtootherorganisms
has also been discussed,
635,636 and attention has been given to the
more complex glycomes (“systems glycobiology”).
637
Twoothermathematicalapproacheshavebeenappliedtodata
sets from studies of mammalian sphingolipid biosynthesis. One
used model-reference adaptive control (MRAC) to investigate
the dynamics of de novo sphingolipid synthesis by Hek cells
stably transfected with serine palmitoyltransferase, and the
MRAC simulations produced results that were comparable to
simulations from a standard model using mass action kinetics,
and suggested that there might be adaptive feedback from
increased metabolite levels.
638 The other approach integrated
lipidomics and transcriptomics data collected by the LIPID
MAPS Consortium (www.lipidmaps.org) for RAW264.7 cells
usingatwo-stepmatrix-basedapproachwhereintherateconstants
obtained from the ﬁrst step were further reﬁned using generalized
constrained nonlinear optimization.
639 The primary focus of the
analysiswastheC16-ceramidebackbonespecies,andtheresulting
model ﬁt the experimental data, with the robustness of the model
being validated through parametric sensitivity analysis.
Sucheﬀortswillnotonlyprovideabetterunderstandingabout
how these molecules are made and function, but also, to help
interpret (and ultimately predict) the outcomes of changes in
precursors, eﬀects of inhibitors, genetic mutations, etc. In addi-
tion, as has been noted by Voit et al.,
636 it also allows the
investigator to test one’s “intuitive grasp of the system through
simulation studies that represent What-If scenarios.” These are
useful not only to test the model, but also to direct researchers
toward potentially interesting directions for future investigation.
6. PERSPECTIVE ON THE CURRENT STATE OF SPHIN-
GOLIPID RESEARCH
Research discoveries over the last several decades have, to a
substantial extent, transformed sphingolipids from enigmas into
intricate puzzles within the ultimate puzzle of life. And unlike an
enigmatic riddle, which is usually perplexing until a simple (and
retrospectively obvious) answer is found, puzzles are hard to under-
standuntilmostofthepiecesareinplace.Findingallthesphingolipid
piecesandtheirplacesisstilladauntingtask,butthisquestispartand
parcel of the omics/systems biology era. One looks forward with
great expectations, and curiosity, for what will be understood next.
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LIST OF ABBREVIATIONS
Cer ceramide
CERK ceramide kinase
CerPE ceramide phosphoethanolamine
CerS ceramide synthase
CERT ceramide transport protein
DHCer dihydroceramide
DES dihydroceramide desaturase
ESI-MS/MS electrospray tandem mass spectrometry
ER endoplasmic reticulum
Fuc fucose
Gal galactose
GalCer synthase; CGalT galactosylceramide synthase
Gg, with subscript for the number of carbohydrates ganglio-
G, with subscript for the subclass ganglioside
Gb, with subscript for the number of carbohydrates globo- or
globo-series
Glc glucose
GlcCer synthase; CGlcT glucosylceramide synthase
GlcA glucuronic acid
GM2-AP GM2-activator protein
Hex A or B hexosaminidase A or B
iGb, with subscript for the number of carbohydrates isoglobo-
or isoglobo-series
Lc, with subscript for the number of carbohydrates lacto-
Lac lactose
GalNAc N-acetylgalactosamine
GlcNAc N-acetylglucosamine
Neu5Ac N-acetylneuraminic acid
nLc neolacto-
Pal-CoA palmitoyl-CoA
Sa1P sphinganine 1-phosphate
SphK sphingosine kinase
S1P sphingosine 1-phosphate
Ser serine
SPT serine palmitoyltransferase
SAP sphingolipid activator protein
SM sphingomyelin
SMase sphingomyelinase
UDP-sugar uridine dinucleotide phosphate sugar
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